Personalizing functional Magnetic Resonance Protocols for Studying Neural Substrates of Motor Deficits in Parkinson’s Disease by Holiga, Štefan
PERSONALIZING FUNCTIONAL MAGNETIC 
RESONANCE PROTOCOLS FOR STUDYING 
NEURAL SUBSTRATES OF MOTOR 
DEFICITS IN PARKINSON ’S DISEASE 
 
D I S S E R T A T I O N  
zur Erlangung des akademischen Grades 
D r .  r e r .  m e d .  
an der Medizinischen Fakultät 
der Universität Leipzig 
 
E I N G E R E I C H T  V O N :   
Štefan Holiga 
geboren am 07/07/1985 in Spišská Nová Ves, Slowakei 
 
A N G E F E R T I G T  A M  /  I N :  
Max Planck Institut für Kognitions- und Neurowissenschaften, Leipzig 
 
B E T R E U E R :  
Prof. Dr. Dr. Matthias Schroeter, MA 
PD Dr. Karsten Mueller 
Doc. MUDr. Robert Jech, PhD 
 
















Personalizing functional Magnetic Resonance Protocols for Studying Neural Substrates of 
Motor Deficits in Parkinson’s Disease 
 
 
Universität Leipzig, Dissertation 
 
 
88 S.1, 136 Lit.2, 10 Abb., 6 Tab., 0 Anlagen. 
 
Referat: 
Parkinson’s disease (PD) is a progressive neurodegenerative movement disorder characterized by 
a large number of motor and non-motor deficits, which significantly contribute to reduced quality 
of life. Despite the definition of the broad spectrum of clinical characteristics, mechanisms 
triggering illness, the nature of its progression and a character of therapeutic effects still remain 
unknown. The enormous advances in magnetic resonance imaging (MRI) in the last decades have 
significantly affected the research attempts to uncover the functional and structural abnormalities 
in PD and have helped to develop and monitor various treatment strategies, of which dopamine 
replacement strategies, mainly in form of levodopa, has been the gold standard since the late 
seventies and eighties. Motor, task-related functional MRI (fMRI) has been extensively used to 
assess the pathological state of the motor circuitry in PD. Several studies employed motor 
paradigms and fMRI to review the functional brain responses of participants to levodopa 
treatment. Interestingly, they provided conflicting results. Wide spectrum of symptoms, 
variability and asymmetry of the disease presentation, several treatment approaches and their 
divergent outcomes make PD enormously heterogeneous. In this work we hypothesized that not 
considering the disease heterogeneity might have been an adequate cause for the discrepant 
results in aforementioned studies. We show that not accounting for the disease variability might 
indeed compromise the results and invalidate the consequent interpretations. Accordingly, we 
propose and formalize a statistical approach to account for the intra and inter subject variability. 
This might help to minimize this bias in future motor fMRI studies revealing the functional brain 
dysfunction and contribute to the understanding of still unknown pathophysiological 
mechanisms underlying PD. 
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1. GENERAL INTRODUCTION 
 The present work deals with improving statistical evaluation of functional magnetic resonance 
imaging (fMRI) in Parkinson’s disease (PD) research. Special focus of this work lies in quantitative 
management of the disease presentation variability in studied subjects, to improve the fMRI 
protocols for studying the neural substrates of motor deficits in PD and to boost scientific 
attempts to uncover still unknown pathophysiological processes involved. This work is organized 
as follows. The General introduction provides fundamental concepts and definitions needed for 
further understanding of the core of the work. It does not provide in-depth notions; on the 
contrary, it introduces the basics of Parkinson’s disease, its pathophysiology, monitoring, 
management and research in context of MRI. The reader is referred to the related work listed in 
the References section for in-depth descriptions of particular concepts of interest. The actual 
work of integrating the movement parameters into the statistical analysis for accounting for intra-
subject heterogeneities, as well as using the clinical scores for removing the confounding effects 
of diverse clinical presentation of the disease follows and is discussed as separate studies in 
different chapters. The General Discussion section then provides an overall summary, examines 
the obtained results in the context of current PD research, explores prospective benefit and 





1.1. PARKINSON’S DISEASE 
 PD is a progressive neurodegenerative movement disorder characterized by loss of 
dopaminergic striatal neurons, manifested by a number of motor and nonmotor features 
(Rodriguez-Oroz et al., 2009) of which the cardinal ones are akinesia, rigidity, tremor and 
postural instability (Jankovic, 2008). PD is the most common basal ganglia movement disorder 
affecting 1 to 5% of those between 65 and 85 years of age (Van Den Eeden et al., 2003). From the 
most prevalent neurodegenerative diseases, PD is the second after Alzheimer’s disease. First 
formal description of PD is dated back to 1817 when James Parkinson in his ‘Essay on the shaking 
palsy’ first detailed specific symptoms and related them to the yet unrecognized clinical syndrome 
(Parkinson, 2002). Few decades later, the founder of modern neurology, Jean Martin Charcot 
proposed that the syndrome should be named after the first descriptor of its manifestations - 
James Parkinson (Lees, 2007). After almost 200 years since the original publication, the syndrome 
still bears his name, but the cause remains to be explored in detail as well as neuroprotective or 
disease modifying therapies to be developed. Nevertheless, during two centuries of tremendous 
technological and scientific advance, effective and promising therapeutic approaches have been 
established that considerably improve the severity of the symptoms and quality of life. Also, 
several clinical, genetic, environmental and protective factors have been discovered and might 
cue for unmasking the triggering and progression of the neurodegenerative processes behind PD 
(Lees et al., 2009). Among obvious aging, also other interesting pathogenetic factors have been 
identified to be linked with PD. Relationship between risk of developing PD and nicotine/caffeine 
consumption, head injury, obesity, lack of exercise, herbicide and insecticide exposure, rural 
living, but also genetic and familial factors have been reported, although PD is mainly regarded as 
a sporadic disorder (Lees et al., 2009). The combination and interaction of these pathogenic 
factors are considered to play an important role in the mechanism of cell death in PD. This 
underlines the importance of regarding PD as a multiple-entity disease, with its facets 
interplaying differently in different individuals (Olanow and McNaught, 2008). The aim of the 
present work is therefore also, with specific application in MRI, to consider PD as a highly 









 Clinical picture of individuals suffering from PD is associated with the presence and 
combination of the following characteristics: akinesia, rigidity, tremor, loss of postural reflexes, 
flexed posture and freezing (Fahn, 2008a). First three are the early symptoms of the disease and 
seem to relate to dopamine deficiency caused by neurodegeneration of dopaminergic neurons in 
substantia nigra (Fahn, 2008a).  Therefore, the early symptoms are usually positively responsive to 
dopaminergic medication (Fahn, 2008a). The later three symptoms, on the contrary, lack to 
respond to levodopa and dopamine agonists, thus are not considered being related to dopamine 
and disrupted dopaminergic mechanisms (Fahn, 2008a). More detailed discussion on 
dopaminergic treatment of PD symptoms can be found later in the text. To describe and 
understand underlying pathophysiological mechanisms behind PD, main clinical features of the 
disease with their types need to be clarified first. Among secondary motor abnormalities, also 
other features classified as nonmotor accompany the dominant, disease defining motor deficits 
very often, including slowness in mental function, sleep disorders, cognitive, behavioral and 
emotional deficits, autonomic and sensory disturbances (Elias et al., 2008; Jankovic, 2008). This 
work will focus on explaining the pathophysiology of the main motor deficits associated with PD 
(akinesia, tremor, rigidity), as it consequently introduces experimental data from investigations of 
only two of them (akinesia, rigidity). 
 Akinesia is the most characteristic symptom of PD and is strictly referred as ‘lack of 
movement’, or shortage of voluntary goal-directed, automatic movements (Elias et al., 2008; 
Jankovic, 2008; Rodriguez-Oroz et al., 2009) and consists of several (sub)types. Hypokinetic 
features relate to reduced frequency and amplitude of spontaneous movement. Most typical signs 





missing facial expressions, reduced gesticulation, reduced arm swinging, problems with 
movements related to daily-life activities like rising from the chair, waving, walking (short 
stepping, not elevating the feet from ground sufficiently) (Rodriguez-Oroz et al., 2009).  Another 
type of akinesia is bradykinesia and it is related to problems in initiating and executing singular 
movements, general disruption of sequential and simultaneous movements. Specific feature of 
bradykinesia is that sequential movements are heavily affected by progressive reduction in 
amplitude and speed (Rodriguez-Oroz et al., 2009). 
 Tremor is another key symptom of PD. It is usually divided to resting shaking (4-7 Hz) or 
action/posture tremor higher in frequency (7-12 Hz) and besides prominence in distal parts of 
extremities can involve shaking of lips, chin, jaw and legs (Elias et al., 2008; Jankovic, 2008). 
Specific situations like stress, maneuvers requiring concentration or voluntary involvement of 
contralateral body part, can be a provoking factor for tremor (Rodriguez-Oroz et al., 2009). It 
should not be confused with another specific movement disorder, essential tremor, as several 
differentiating features have been established to distinguish them (Jankovic, 2008). 
 Rigidity, the increased muscle tone, is the only motor symptom, which might be associated 
with pain. Attributes of rigidity, stiffness and resistance of the muscles are detected by an 
examiner with palpation at rest, often experiencing a cogwheel phenomenon while moving the 
patient’s limbs, neck or shoulders (Fahn, 2008a; Rodriguez-Oroz et al., 2009). Both extension and 
flexion of muscles are affected by rigidity, with increased resistance to stretching and facilitation 
of shortening reaction (Rodriguez-Oroz et al., 2009). 
PATHOPHYSIOLOGY 
 There is no single model for PD explaining all its different features. In the early eighties a 
remarkable step forward in research of PD emerged with a discovery that an agent 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) has a highly selective destructive effect on 
dopaminergic neurons in substantia nigra pars compacta (SNc), a structure predominantly 
affected by neurodegeneration in PD (Wichmann and DeLong, 2008). This compound was then 
used to induce Parkinsonism in primates, a prerequisite for development of an early animal 





with a great impact on further PD research. Numerous aspects of the disease can be explained 
using this model, although several expansions have been made to it to account for unexplained 
clinical paradoxes and observations (Rodriguez-Oroz et al., 2009). The model uncovers functional 
architecture of subcortical nuclei called basal ganglia (BG) (predominantly affected by loss of 
dopaminergic neurons in PD), their integration with cortical areas in the healthy and 
Parkinsonian state. BG embody a complex network of loops responsible (not exclusively) for 
movement control, consisting of striatum (caudate nucleus, putamen), external and internal 
segments of globus pallidus (GPe, GPi, respectively) and nuclei, the subthalamic nucleus (STN), 
the substantia nigra (SN) divided to substantia nigra pars compacta (SNc) and pars reticulate 
(SNr). Functional architecture of BG can be divided into several circuits. Besides motor circuit, 
associative, limbic, oculomotor and orbitofrontal circuits have been described, too (Obeso et al., 
2002). This work will however focus solely on the motor circuit, the one dominantly affected by 
PD. The motor cortico-subcortical pathways are functionally clearly segregated, according to 
cortical area of the input origin and the basal ganglia region, where the particular pathways reside 
(Wichmann and DeLong, 2008). The somatotopic organization of this circuit is depicted in Figure 
1. Physiologically, this circuit seems to be responsible for controlling the movement parameters 
(amplitude, velocity, rate), the initiation and execution of movements, sequencing of them, 
switching between movements and motor programs (Wichmann and DeLong, 2008). 
 
Figure 1. Somatotopic architecture of the motor circuit. Regions responsible for leg movements are located dorsal and medial, those 
responsible for face movements lying ventral and lateral, and areas responsible for arm movements lying in-between. Input structure of the 
basal ganglia in the motor loops is putamen and STN (receiving input from cortical structures), whereas SNr and GPi serve as output 
structures, sending inhibitory projections to thalamus and brainstem. Projections from SNr and GPi to thalamus are regarded to play the most 
important role in involvement of basal ganglia in the motor function. Reprinted from The Lancet Neurology, Vol. 8, Rodriguez-Oroz et al., 
Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms, Pages 1128-1139, Copyright (2008), with 





 The striatum contains several types of cells. Majority of them are GABAergic (neurons, that 
produce inhibitory neurotransmitter γ-Aminobutyric acid [GABA] as their output) medium spiny 
neurons, which project to both segments of GP (i.e. GPe and GPi) and receive inputs from 
glutamatergic inputs from cortex and thalamus. Also other types of neurons, e.g. cholinergic 
interneurons and classes of GABAergic interneurons, are present in striatum in a relatively 
smaller quantity, however are believed to be involved in significantly affecting the striatal 
outputs. GPe, GPi and SNr consist mainly of GABAergic neurons, STN of glutametergic neurons 
and SNc’s neurons are dopaminergic (Wichmann and DeLong, 2008).  
 In a healthy motor circuit (Figure 2A), the motor cortical areas (area 4, the premotor cortex, 
the supplementary motor area) and the primary somatosensory cortex project the excitatory 
axons to the putamen, from which the GABAergic medium spiny projection neurons are directed 
to the output structures of BG, internal segment of the globus pallidus (GPi) and SNr (Figure 1, 
Figure 2). Two separate pathways maintain the direction: direct pathway neurons connect the 
putamen with GPi/SNr directly and monosynaptically. Trisynaptic indirect pathway neurons 
connect their GABAergic axons to the external segment of the globus pallidus, which is connected 
to the STN. STN then directs the neurons to the output structures GPi/SNr (Obeso et al., 2002) 
(Figure 2). SNc is the source of dopaminergic cells, which have an intrinsic, continuous effect on 
motor activity and fire tonically. Dopaminergic neurons from SNc excite the D1 neurons 
(SNc→putamen; Figure 2A) affecting the direct pathway by inhibiting the putaminal connections 
to GPi (putamen→GPi; Figure 2A), following with inhibitory connections to ventral lateral 
nucleus of thalamus (VL; GPi→VL; Figure 2A).  As opposed to direct pathway, in the indirect 
pathway, dopaminergic neurons from SNc inhibit the D2 neurons (SNc→putamen; Figure 2A), 
leading to inhibitory connections to GPe (putamen→GPe; Figure 2A), which results in inhibitory 
effect on connection GPe-STN (GPe→STN; Figure 2A), these then make an excitatory connection 
with GPi (STN→GPi Figure 2A).  Both pathways result in excitation of cortex by the ventral lateral 
nucleus of thalamus (VL), which then manages the signal transports to brain stem and spinal cord 
and subsequent neuronal work of the rest of the body involved in the movement. Thus, the 
movement control in BG is maintained through the activation of the direct pathway resulting in 
reduced firing in GPi/SNr and movement facilitation, whereas during the activation of indirect 
pathway, the movements are suppressed (Rodriguez-Oroz et al., 2009). It is a balance between 
indirect and direct pathways that seems to be crucial for BG output control (Rodriguez-Oroz et 






Figure 2. The classic pathophysiological model of the basal ganglia in form of cortico-subcortical motor loops. A) Healthy motor loop. B) 
Parkinsionian motor loop. See the text for detailed description. Green arrows represent excitatory activity, red arrows represent inhibitory 
activity. Thickened and thinned connections refer to hypoactivity and hyperactivity, respectively. SNc: substantia nigra pars compacta; GPi: 
globus pallidus pars interna; GPe: globus pallidus pars externa; STN: subthalamic nucleus; SNr: substantia nigra pars reticulate; VL: 
ventrolateral thalamus. Reprinted from The Lancet Neurology, Vol. 8, Rodriguez-Oroz et al., Initial clinical manifestations of Parkinson’s 
disease: features and pathophysiological mechanisms, Pages 1128-1139, Copyright (2008), with permission from Elsevier. 
 In Parkinsonian state, the depletion of dopamine in SNc results in increased activity in the 
indirect pathway (putamen→GPe; Figure 2B) with hyperactive STN (STN→GPe; Figure 2B), and 
diminished activity in the direct pathway (putamen→GPi; Figure 2B). This leads to increased 
GPi/SNr output inhibition (GPi/SNr→; Figure 2B) of the VL and thus to reduced activation of 
cortical regions (Rodriguez-Oroz et al., 2009). Thus, changes in neuronal firing rate in the GPi 
and SNr, hence inhibition of the VL nucleus of the thalamus resulting in reduced excitation of the 
cortex are leading to the emergence of the main positive pathological motor features of the 
disease – akinesia and bradykinesia. PD motor signs begin typically in one limb segment and 
focally, with falling dopamine concentrations in the contralateral putamen of about 60% 
(Rodriguez-Oroz et al., 2009). 
 As mentioned earlier in the text, the presented model is based on MPTP-induced Parkinsonism 
in primates. Although it has been very helpful and important for understanding the 
pathophysiological mechanisms of PD and development of new therapies, it is incapable of 
explaining a number of paradoxes (Rodriguez-Oroz et al., 2009). For instance, the increased firing 





thalamus to cortex does not explain the two of the positive key motor symptoms – rigidity and 
tremor, as is does not succeed in explaining a number of findings in recent study of human PD 
subjects (Wichmann and DeLong, 2008). Therefore, many aspects of PD remain still peculiar, as 
no definitive pathophysiological model has been discovered, giving a ground for further 
investigations and developments. 
1.3. DIAGNOSIS AND MONITORING 
 Several parkinsonian states with symptoms and signs overlapping with PD have been 
discovered and require to be considered, when diagnosing PD (Fahn, 2008a). Prior to treatment, 
the idiopathic PD must be differentiated from disorders such as essential tremor, drug-induced 
parkinsonism, corticobasal degeneration, but also from Parkinson-plus syndromes as multiple-
system atrophy, supranuclear palsy, and other secondary parkinsonisms. Misdiagnosis at this pre-
treatment, early stage of the disease might lead to poor response to antiparkinsonian medication 
and bad prognosis (Clarke, 2004). Over the years of researching and treating PD, several subtypes 
of PD have been categorized also, differing significantly in disease progression, response to 
treatment, symptomatic dominance. For instance, sub-types as predominant resting tremor (T-
sub-type), primarily marked as akinesia and rigidity (AR-sub-type), or postural instability gait 
difficulty (PIGD type) have been classified and used for research and clinical purposes (Jankovic et 
al., 1990). Since there is no definitive laboratory diagnostic test for PD, the diagnosis is mainly 
based on clinical criteria (Jankovic, 2008) and is usually evaluated by the movement disorders 
specialist. A number of clinical criteria have been established and one of the most common are 
UK Parkinson’s Disease Society Brain Bank diagnostic criteria (Hughes et al., 1992). Even though 
the accuracy of the diagnosis can be significantly improved using these criteria, up to 10% of 
patients diagnosed with PD during their life had to be reclassified after post-mortem tests (Tolosa 
et al., 2006). Especially in the early phases of the disease, when the symptoms of different 
parkinsonisms are overlapping, the diagnosis is very challenging. PD is frequently misdiagnosed 
as essential tremor, Alzheimer’s disease and vascular parkinsonism (Jankovic, 2008). However, the 





basis of PD and its therapy, and count as potentially promising biomarker for the early disease 
detection. A separate section later in the text is dedicated to imaging applications in PD research.  
 Wide spectrum of symptoms, variability and asymmetry of the disease presentation, several 
treatment approaches and their outcomes make PD enormously heterogeneous. New insights to 
the pathophysiology and the manifold nature of the disease highlight the importance to monitor 
it and its progression over time and measure the patients’ clinical outcomes in a quantitative 
manner. Several rating scales have been developed in the past to evaluate the impairment and 
disability of patients with PD (Ramaker et al., 2002), of which the Unified Parkinson’s Disease 
Rating Scale (UPDRS) is the one most commonly used (Movement Disorder Society Task Force on 
Rating Scales for Parkinson's, 2003), for both research and clinical purposes. UPDRS embraces an 
expansive clinical spectrum of PD and has a wide applicability. It is composed of four distinct 
parts, each containing multiple items, of which each is integer-rated. The rating has a cumulative 
character, i.e. more impairment and disability results in a higher UPDRS score. The first part 
evaluates non-motor aspects of experiences of daily living, the second part evaluates the motor 
aspects of experiences of daily living, the third part is the motor examination and assesses the 
motor aspects of the disease, and the fourth part examines the motor complications (i.e. 
dyskinesias and motor fluctuations related to pharmacological therapy) (Movement Disorder 
Society Task Force on Rating Scales for Parkinson's, 2003). The most relevant part of UPDRS for 
the current work is the third part (UPDRS-III), which assesses the motor signs of PD. Various 
motor tasks and tests, sometimes involving the examiner to interfere, are performed and rated in 
UPDRS-III, e.g. facial expression, finger tapping, hand movements, arising from chair, gait, 
postural stability and others. Where applicable, the items are evaluated for both right and left 
body side separately, which allows assessing the lateral involvement of motor disability in PD, 
often being expressed as dominant for one body side. It is important to notice the expansive 
multidimensionality of UPDRS, containing more than 70 items, of which a high number is 
subdivided. Within each part of UPDRS, especially within UPDRS-III having the highest number 
of items, there is high likelihood of intra-subject asymmetry and inter-subject variability. More 
specifically, two patients with the same UPDRS-III score might possibly express vast symptomatic 
heterogeneities justified by the individual motor items and their sub-items. Despite the problems 
like ambiguities, insufficient discrimination between disease categories, missing elements, the 
broad utilization, short average time requirement for completion of the full scale (10-20 min) and 





1.4. TREATMENT OF SYMPTOMS 
 No neuroprotective drug that would slow down or stop the progression of the disease has 
been proven yet, although there are clinical trials, which suggested a neuroprotective character of 
some drugs (Clarke, 2004). Current therapy is providing symptomatic benefit solely, and is aimed 
on maintaining the motor and non-motor presentation of the disease on a satisfactory level. Here, 
we introduce the treatment of the key motor characteristics of the disease only, since the current 
experimental work was focused on investigations of the affected motor circuitry. A sequence of 
breakthrough discoveries gave rise to the effective pharmacological treatment of motor symptoms 
as we know it today: 1) discovery of dopamine and mechanisms of its biosynthesis provided us 
with important observation that enzyme dopa decarboxylase converts levodopa to dopamine, 
allowing for formation of dopamine in the brain from an exogenous source, overcoming the 
obstacle of blood-brain barrier; 2) identification of dopaminergic pathways and measurements of 
the dopamine concentrations in the human brain; 3) identification of striatal dopamine deficiency 
in postmortem PD patients; 4) initial tests of levodopa in PD patients, which even then 
recognized its spectacular efficacy, but also number of limitations, moreover provided a 
revolutionary and up to this time dominating strategy to treat the disease (Fahn, 2008b). 
Dramatic improvement in motor function has been observed at these experimental stages with 
levodopa, patients were getting out of their wheelchairs and walking (Fahn, 2008b). After this 
series of major findings, the dopamine replacement treatment - the era of levodopa has begun. 
Since the late 1970s and 1980s, more than a decade or two after the first tests in PD patients, 
levodopa has become ‘the gold standard’, has been the major therapeutic advance in the motor 
symptomatic therapy and has been considered as the most effective symptomatic treatment of PD 
(Clarke, 2004).  
 Despite its outstanding effectiveness, levodopa treatment triggered a number of serious 
adverse effects. In fact, most patients experience complications over the chronic levodopa 
treatment course (Fahn, 2008b). One of the early immediate side effects was nausea and vomiting 
due to activation of dopamine-sensitive receptors in area postrema of the medulla not being 
protected by blood-brain barrier (Olanow, 2004). Development of peripheral dopa decarboxylase 





this metabolic step to happen centrally, made levodopa more potent and minimized these side 
effects substantially (Fahn, 2008b). More severe complications associated with the long-term use 
of levodopa as dyskinesias, non-dopaminergic motor and non-motor fluctuations, 
neuropsychiatric symptoms caused that levodopa mono-therapy is no longer an exclusive strategy 
to treat PD and drove the development and approval of a significant number of other treatment 
options and approaches during the levodopa era (Rascol and Katzenschlager, 2008). 
Anticholinergics, amantadine, MAO-B inhibitors, COMT inhibitors and dopamine agonists 
(Clarke, 2004), to name few, have been widely studied and compared with levodopa, however 
they can, at best, complement, or be used as an additional strategy. However, discussing their 
effects, advantages and disadvantages is out of scoop of this report and will be not discussed 
further.  
 There is no direct and one-way therapeutic strategy and the treatment must be tailored at 
each stage (de novo PD, later stage of PD) of the disease for each patient, considering progression 
and history of the disease, responsiveness, efficacy, side effects, but also economical aspects of the 
therapy (Rascol and Katzenschlager, 2008). In the literature, there has been an extensive debate 
related to levodopa. It concerned when to start the treatment (Fahn, 2008b), the potential toxicity 
of levodopa, which may hasten the disease progression (Olanow and Obeso, 2011), but also 
suggestions, that levodopa may be neuroprotective in the early stages of the disease (Fahn et al., 
2004). These issues still remain unsolved and this further suggests that the data are not conclusive 
yet and there is a lot of room for further advances and developments regarding the mechanisms 
underlying the levodopa treatment. Nevertheless, levodopa remains without question the most 
effective pharmacological option for controlling PD symptoms. 
 Proposed therapies fail to provide a satisfactory management of the advanced stage of the 
disease in a significant number of PD patients. Surgical interventions are available and suitable 
alternatives for well-selected patients. Ablation techniques as pallidotomy or thalamotomy, which 
have been used as a therapy for PD for more than 50 years have been replaced by deep brain 
stimulation (DBS), where a target (usually STN or GPi) is continuously stimulated with an 
implanted electrode using voltages around 2.0 – 3.5 V, relatively high frequencies (~130 Hz) and a 
pulse width of 60 μs (Benabid et al., 2009) after a complex surgical procedure, where the 
electrodes and stimulator are implanted in patient’s body. All of the cardinal PD features, 





Multicentre randomized controlled study showed a noteworthy improvement in quality of life of 
patients, which underwent DBS of STN, but also their caregivers (Benabid et al., 2009). No direct 
comparisons between DBS of STN and GPi exist and the decision on the stimulation site must be 
carefully selected according to the patients’ clinical picture and the movement disorders 
specialist’s experience. There are some adverse effects of DBS, which are mainly associated with 
surgical intervention or post-surgical complications (Olanow, 2004), but another side effects as 
weight gain, mood changes and decline of word fluency have been reported, as well (Benabid et 
al., 2009). Microlesion-related side effects are usually transient and usually cause no clinical 
complications. Even though the DBS was not investigated in the current work, all of the patients 
investigated were actually selected for the DBS of STN, underwent the surgical procedure and 
have been stimulated. Promising and unique data have been collected for their post-surgery state, 
including on stimulation, and we address the potential future link of this work to this data in the 
General Discussion section of this thesis. 
1.5. NEUROIMAGING 
 Over the last 25 years the booming development in field of neuroimaging allocated a lot of 
room for further alternatives in detecting of functional and structural changes in PD, providing 
insights into disease abnormalities, understanding the pathogenesis of the disease and fueled the 
scientific community to develop potential disease-modifying therapies, or a definite diagnostic 
tool that would detect the disease initiation and assess its progression quantitatively (Stoessl et 
al., 2011). 
 Early human imaging studies of PD were mainly related to assess the role of basal ganglia 
dopamine function, cerebral blood flow or glucose metabolism using positron emission 
tomography (PET), or single-photon emission computed tomography (SPECT) (Antonini and 
DeNotaris, 2004; Brooks, 2001, 2010; Rowe and Siebner, 2012; Stoessl et al., 2011). With PET and 
SPECT, a radionuclide/radiotracer is injected into the studied subject and the subsequent uptake 





Although their principle disadvantage of being invasive, these imaging modalities might be very 
useful and well suited to early detection of the disease, and contribute as a useful biomarker for 
monitoring the disease history and progression (Stoessl et al., 2011). PET/SPECT is irreplaceable 
and ideal for studies of molecular and neurochemical function, where no other imaging 
modalities can be applied or compete. With recent discoveries of tracers targeting on other 
physiological phenomena than dopaminergic, PET/SPECT might be helpful in investigating motor 
features unrelated to dopaminergic dysfunction, or non-motor features of PD (Stoessl et al., 2011). 
 Over the recent years of enormous progress in MRI, it has become widely available and its 
role in diagnosing and monitoring of parkinsonian syndromes has progressed rapidly. Contrary to 
PET/SPECT, physical principle of MRI is based on spin properties of water molecules in human 
tissue, which allows detecting the local magnetic field changes caused by relaxation of spins using 
various imaging sequences. The major advantage of MRI compared to PET/SPECT is non-
invasiveness; it does not involve exposure to radiation. Further advantages include excellent 
spatial and considerable temporal resolution in comparison to PET/SPECT. Several applications of 
MRI have been reported for studying structural and functional abnormalities in PD. With today’s 
MR hardware capabilities, field strengths and methodological advances, the investigators are able 
to image even the smallest deep brain structures and nuclei and observe sub-millimeter 
morphological changes. One of the dominant examples in morphological MR imaging is voxel 
based morphometry (VBM), which can statistically assess morphological differences of 
participants from T1-weighted structural images. Several studies have reported gray matter 
reduction in frontal cortical areas using this approach (Stoessl et al., 2011). Using automated 
algorithms for segmentation of brain structures the volumetric changes can be assessed, or shape 
of associated brain structures can be quantified (Stoessl et al., 2011). Further morphological 
application of MRI is diffusion tensor imaging (DTI), where the diffusion of water is measured 
and evaluated by the assumption that water molecules are diffusing along the white matter tracts. 
Using this approach and calculating the fractional anisotrophy from the diffusion tensor, anatomy 
and the integrity of the white matter fiber tracts in the brain can be evaluated. Several PD studies 
have reported decreased fractional anisotrophy values in substantia nigra, frontal lobes, the genu 
of corpus callosum and the superior longitudinal fasciculus (Stoessl et al., 2011).  
 A widely used imaging approach for investigating functional changes in PD is fMRI. FMRI 





particular sort of fMRI signal, signal acquired using blood oxygen level-dependent (BOLD) 
contrast mechanism is the one, which revolutionized the world of neuroimaging. Increased local 
neuronal firing rate is associated with the local CBF increase and the increase in oxygen 
consumption. There is a mismatch between the two and paradoxically, CBF increase exceeds the 
increase of oxygen consumption leading to reduced concentrations of deoxyhemoglobin. 
Deoxyhemoglobin is paramagnetic, thus acts as an endogenous contrast agent, causing the local 
magnetic field inhomogeneities detected by BOLD sensitive imaging sequences. Hence, the BOLD 
signal relates the changes in CBF, cerebral blood volume (CBV) and blood oxygenation to changes 
in local neural activity and is widely used as an indirect non-invasive measure of neural activity 
(Logothetis, 2003). During task-related fMRI experiment, time series of MR BOLD-sensitive 
volumes are collected over time, while the participant performs a controlled cognitive or motor 
task. Timing of the experiment is then used to predict the shape and timing of the BOLD response 
and to consequently reveal its correlates with the measured time-courses in particular voxel, in 
form of a mass-univariate statistic applied to each voxel. When the time-course for a particular 
voxel is correlated with the predictor to a certain degree, the voxel is color-coded. Spatial maps of 
localized neural activity are then formed this way. Depending on the research question asked and 
experimental design conducted (e.g. factorial design with an experimental manipulation and 
repeated sessions), the data from multiple subjects are usually combined and compared in higher-
level statistics, to increase the power of statistics and to obtain the group activity maps less 
sensitive to outliers, revealing the main effects of experimental factors’ levels, or the interactions 
between them. 
 Because of its non-invasive nature, fMRI has been extensively used to investigate various 
aspects of PD including cortico-striatal network function in PD, motor and non-motor features of 
the disease (Dagher and Nagano-Saito, 2007; Rowe and Siebner, 2012). Several motor tasks have 
been used to investigate the motor circuitry in PD, and there is an evidence of abnormal 
activation in patients performing manual motor tasks in various brain areas compared to healthy 
controls, with a great deal of diversity (Rowe and Siebner, 2012). The activation/deactivation 
patterns vary considerably among different studies and the results are also not consistent with the 
results obtained by the early PET CBF studies. Review papers report the difference in motor 
paradigms as the potential reason for discrepant results and as a confounding effect (Dagher and 
Nagano-Saito, 2007; Rowe and Siebner, 2012). Increased activation in SMA during paced and over-





task. Furthermore, decreased activity in the SMA and striatum, increased activity in premotor 
cortex have also been reported (Rowe and Siebner, 2012). Earlier repeated measures designs 
challenging the effect of levodopa treatment have also been shown, however similarly, revealing 
conflicting results without any consensus (Dagher and Nagano-Saito, 2007; Rowe and Siebner, 
2012). The authors speculated, that the dominant source of the discrepant results in the studies 
might be that with different motor paradigms, the selection, automatism or self-generation, 
planning and monitoring of the actual movement varies considerably and influences the results.  
1.6. THE CURRENT WORK IN CONTEXT OF FUNCTIONAL 
MAGNETIC RESONANCE IMAGING 
 Surprisingly, only a small number of the studies investigating neural substrates of motor 
deficits in PD using fMRI considered the fact of the vast variability of the disease itself, as 
mentioned earlier in the text. Furthermore, studies investigating current effective therapies (in 
this particular case levodopa medication) mainly did not consider the additional and substantial 
motor and non-motor symptomatic variability caused by the outcome of the dopaminergic 
treatment. In their explanations they only focused on relating the result inconsistencies to the 
different nature of experimental paradigms, they did not deem for more natural and potential 
lower-level source of bias, the intra/inter patient variability in their motor outcome. Considering 
that the patients are suffering from a movement disorder, the assumption of the motor 
experiment results being markedly compromised by the motor outcome variability is completely 
intuitive and perfectly sound. In this work, we centered our focus on this assumption and tested 
the sensitivity of motor fMRI experiments investigating the effect of levodopa challenge in PD 
patients with and without considerations of motor outcome of patients, in terms of quantitatively 
measuring and controlling their movement, consequently implementing the recordings in the 
statistical analyses, and tweaking the group-level statistical predictions using the clinical metrics 
of patients in the group models of neural activity. We hypothesized, that regarding this fact 





samples, thus regularize different proportion of involvement in relevant brain systems, 
empowering unbiased and objective comparisons among functional imaging studies of PD 
pathophysiology. 
 The first part of the work focuses on accuracy in modeling of the predictor (i.e. the BOLD 
response) for each individual in a simple visually-guided motor fMRI experiment. This approach 
is centered on intra-session variability, and intends to show that undesirable effects of movement 
variability might appear even within-session; changes in the amplitudes, or onset/offset time of 
the movement or other hidden movement features might lead to different brain responses, which 
generic type of BOLD modeling is incapable of detecting, leading to less sensitive statistical 
inferences and invalid results. We propose a quantitative and personalized method for BOLD 
prediction by measuring the motor performance of each patient with multisensory-apparatus and 
incorporating it into the modeling. An experimental manipulation, the dopaminergic challenge is 
used for introducing a secondary source of motor variability, originating from the effect of drug 
rather than from the diverse nature of the diseased state of participants. Both generic, widely used 
method and the newly proposed approach is then statistically assessed and compared. 
 The second part of the current work aims on targeting the inter-subject variability in the 
group level statistical modeling of brain activity, i.e. the variability between the measurement 
sessions. The current state of the art of motor fMRI imaging in Parkinson’s disease is reviewed in 
this work, resulting in a surprising finding that the majority of the PD fMRI studies have not been 
accounting for the between-session symptomatic state of participants and not considered 
potentially different pathophysiological mechanisms, caused by the considerable heterogeneity of 
PD. Using the same experimental design as within the first part, we show, involving repeated 
sessions with the levodopa intervention, that more profound considerations are needed even if 
the population sample has seemingly uniform demographics and clinical characteristics, to build 
more potent statistical method for obtaining reliable results. Two statistical approaches for 
considering the potential confounding effect are formulated, with incorporating the widely 













2. ACCOUNTING FOR MOVEMENT INCREASES SENSITIVITY IN 
DETECTING BRAIN ACTIVITY IN PARKINSON’S DISEASE 
2.1. INTRODUCTION 
 PD is a progressive neurodegenerative disorder causing BG dysfunction (Rodriguez-Oroz et 
al., 2009). It is characterized by a large number of motor and non-motor deficits, which 
significantly contribute to reduced quality of life. Despite the definition of the broad spectrum of 
clinical characteristics and criteria for diagnostics (Jankovic, 2008), mechanisms triggering illness, 
the nature of its progression, and the character of therapeutic effects are still a matter of debate 
(Antonini et al., 2009; Benabid et al., 2009; Davie, 2008; Lees et al., 2009; Rodriguez-Oroz et al., 
2009). Motor symptoms are key features of clinical criteria and are essential for the diagnosis of 
PD and its differentiation from related disorders. Bradykinesia, tremor, rigidity, and postural 
instability are regarded as cardinal symptoms and are associated with difficulties with planning, 
initiating and executing movements, performing sequential and simultaneous tasks, progressively 
reduced magnitude of sequential movements, involuntary choreatic and dystonic movements, 
hesitation in initiation, or finishing voluntary movements (Jankovic, 2008). 
 For the last two decades, PET and fMRI have been used to investigate the neural substrates 
of motor deficits in PD (Brooks, 2001; Dagher and Nagano-Saito, 2007). More recently, fMRI 
studies have tended to outnumber PET studies due to their advantages of greater temporal and 
spatial resolution and non-invasiveness (Dagher and Nagano-Saito, 2007). Frequently used block-





movement sequences, to investigate the neural basis of PD patients' motor performance. This is 
motivated by a higher degree in limitations of potential movement complexity and larger hand 
cortical representation (Lotze et al., 2000). Prevalent tasks in investigating the brain motor 
circuitry in PD are sequential finger movements, which are also part of the widely used UPDRS 
(Parkinson's Disease Foundation (U.S.), 1986). This clinical scoring system rates the symptomatic 
severity of the disease. It is easily accessible and suitable for providing a direct comparison 
between subjects or use in longitudinal studies. 
 To assess the correctness of task execution and confirm comparable performance among PD 
participants, previous imaging studies have used push buttons (Kraft et al., 2009; Wu and Hallett, 
2005; Yu et al., 2007), video-camera recordings (Foki et al., 2010; Lewis et al., 2007; Moraschi et al., 
2010), observers/raters (Sabatini et al., 2000), custom-built systems (Ng et al., 2010), or no specific 
arrangements (van Nuenen et al., 2009). Prior training sessions have also been employed 
(Buhmann et al., 2003; Holden et al., 2006; Lewis et al., 2007; Peters et al., 2003; Sabatini et al., 
2000; Sen et al., 2010) to practice the task and obtain adequate performance. A recent study 
(Helmich et al., 2011) assessed the motor outcome of PD patients quantitatively using 
electromyography (EMG) and fMRI. In particular, measured fluctuations of the tremor amplitude 
were used to identify tremor-related brain activity. However, no study has explicitly considered 
the effect of accounting for the motor outcome on the sensitivity in detecting task-related brain 
activity in fMRI experiments with PD patients so far. 
 The analysis and interpretation of task-dependent fMRI data is highly dependent on the 
choice of the hemodynamic response (HR) model. Hemodynamic timing variability limits the 
interpretation of fMRI data because of its relatively rapid time scale ranging from milliseconds to 
seconds (Moonen et al., 1999). Accurate modeling of motor-related brain responses in fMRI 
investigations therefore relies on the experimental timing to a great extent. Another important 
characteristic is the movement amplitude. Large-amplitude movements seem to lead to an 
increased blood-oxygenation level dependent (BOLD) response in several brain regions as 
compared to small-amplitude movements (Waldvogel et al., 1999). Other factors influencing the 
HR include force (Thickbroom et al., 1998), reaction time (Mohamed et al., 2004), and movement 
rate (Lutz et al., 2004; Sadato et al., 1997). Due to this high sensitivity of the BOLD response, 
modeling of fMRI data should ideally consider all potential factors affecting the shape or timing. 





of ~1% in BG (Scholz et al., 2000), regions that are predominantly affected by PD. In investigations 
of PD subjects, this becomes even more apparent due to motion variability because of 
bradykinesia and hypokinesa, impaired initiation of the movements after internal or sensory cues, 
frequent hesitation or freezing of the movements, resting tremor and dyskinesias while 
performing motor tasks. The motor abnormalities in PD are not always easily differentiable and 
may even manifest as a mixture of several symptoms with a great degree of variability between 
patients. Unfortunately, all this may compromise the correct interpretation of the functional 
imaging of motor tasks in general. In investigations of therapeutic effects, for example medication 
or deep brain stimulation, requiring repeated fMRI sessions and where the motor outcome of 
participants may even dramatically change between the sessions intra-individually, experimental 
accuracy and reproducibility is a critical issue. Therefore, it is impossible to achieve favorable 
accuracy in modeling the BOLD response without explicitly and quantitatively assessing 
participants' motor outcomes. Without such knowledge, statistical tests relying on the standard 
BOLD model will be degraded by inappropriate estimates of partial regression coefficients, ß, and 
thus result in biased, unreliable, and potentially invalid conclusions. The goals of the current 
study were to confirm this statement and present a robust solution to problems arising from it. To 
emphasize the possibility of within-subject, but also between-subject, task-related deviations 
caused by the broad motor heterogeneity of the disease, we designed the study with repeated 
measurement sessions, by employing experimental manipulation (levodopa medication) having a 
radical, and more importantly, individual task-dependent effect on the response of the 
participants. With this experimental setup we hypothesized that in contrast to generic fMRI 
statistics, accounting for deviations in task execution quantitatively in BOLD modeling improves 
the accuracy of detecting individual motor activity by reducing ‘type II’ errors. Consequently, this 
should result in increased sensitivity of detecting the patients’ brain responses to levodopa 
medication on the group level. 
 Several attempts to record kinematic information on-line during motor tasks for 
consideration in hemodynamic modeling have already been proposed. Most prevalent and 
established techniques employ simultaneous fMRI and EMG recordings in healthy subjects to 
validate brain activation by their relation to the EMG recordings (MacIntosh et al., 2007; 
MacIntosh et al., 2004; van Duinen et al., 2008; van Rootselaar et al., 2007). An optoelectronic 
motion capture system monitoring a stroke patient (Casellato et al., 2010) or a custom-built 





instrumented, MRI-compatible gloves for capturing movements during fMRI investigations have 
been introduced. Specifically, gloves were used in investigations of correlates of finger movements 
and brain activity (Horenstein et al., 2009) or for qualitative control in a study in stroke patients 
(Sharma et al., 2009). In the current work, the gloves were employed during simultaneous 
recordings of fMRI and kinematics in serial investigations of PD patients to evaluate potential 
improvements in the statistical data analysis. 
2.2. MATERIALS AND METHODS 
 
2.2.1. PATIENTS 
 Twelve right-handed male patients with advanced akinetic-rigid type of PD (Hoehn-Yahr 
stages II-III, 45-64 years of age) (Hoehn and Yahr, 1967) were recruited for this study. As basis for 
the diagnosis, the UK PD Society Brain Bank Criteria (Hughes et al., 1992) were used. All patients 
included in the study met the criteria. Each of them gave written informed consent prior to 
participation in accordance with the declaration of Helsinki. Ethics Committee of the General 
University Hospital in Prague, Czech Republic approved the protocol of the study. Severity of 
patients' motor symptoms was clinically assessed using the motor examination (part III) of the 
UPDRS. UPDRS-III score sheets were used to evaluate hemibody scores comprising information 
about dominant lateral involvement of PD by summing rigidity (sum of item 22), akinesia (sum of 
items 19, 23-26, 31), and tremor (sum of items 20, 21) for each hemibody separately (Movement 
Disorder Society Task Force on Rating Scales for Parkinson's, 2003; Parkinson's Disease 
Foundation (U.S.), 1986). Patients' clinical and demographic characteristics are summarized in 





  Patients were measured in two conditions, once after overnight withdrawal of levodopa 
(‘levodopa OFF’ condition) and once one hour after administration of 250 mg of levodopa / 25 mg 
carbidopa (‘levodopa ON’ condition) (Isicom 250, Desitin Arzneimittel, Hamburg, Germany). Any 
other anti-parkinson’s medication (dopamine agonists, selegiline, amantadine, anticholinergics) 
was not administered for four days before the medication-free condition measurement. 
Characteristic Mean (SD) Range 
Age (years) 56.0 (7.0) 45 - 64 
Gender (M/F) 12/0 - 
Disease duration (years) 12.4 (2.0) 9 - 15 
Levodopa treatment duration (years) 9.3  (3.0) 5 - 13 
Motor complications duration (years) 5.0 (3.0) 2 - 12 
UPDRS*-III: levodopa OFF 33.5 (9.0) 20.5 – 47.0 
UPDRS*-III: levodopa ON 9.6 (4.0) 1.5 – 20.5 
MMSE† 28.9 (1.0) 28 - 30 
UPDRS* - Unified Parkinson’s Disease Rating Scale. MMSE† - Mini Mental State Examination. 
Table 1. Demographic and clinical summary of studied patients (N=12). 
2.2.2. MRI DATA ACQUISITION  
 Functional imaging was performed on a 1.5T MAGNETOM Symphony scanner (Siemens, 
Erlangen, Germany) using a birdcage head coil. A T2*-weighted gradient-echo echo-planar 
imaging (EPI) sequence (flip angle 90°; repetition time, TR = 1 s; echo time, TE = 54 ms) was used 
for BOLD fMRI. Ten oblique slices (thickness 3 mm; 1-mm slice separation; nominal in-plane 
resolution 3×3 mm²) were acquired. The slices were oriented along the central sulcus, covering 
the primary sensorimotor cortex and the basal ganglia. Additionally, a three-dimensional T1-
weighted dataset was acquired with a magnetization prepared rapid acquisition gradient echo 
(MP-RAGE) sequence in 160 axial slices 1.65-mm thick with nominal in-plane resolution 0.9×0.9 
mm² and field of view (FOV) 238 mm covering the entire brain and cerebellum (inversion time, TI 







2.2.3. MOVEMENT MONITORING SET-UP 
 Patients' motor outcome was recorded using instrumented, MRI-compatible, bilateral 
sensory gloves (5th Dimension Technologies, Irvine, CA, USA). The glove contains no 
ferromagnetic parts and communicates with a control box placed outside the scanner room via 
optical cable. The control box is connected with a remote computer via USB or serial port. The 
glove is made of a stretch lycra material (fits to many hand sizes) with embedded proprietary 
fiber-optic-based flexor technology sensors. Two sensors per finger measure flexion of its knuckle 
and first joint. One sensor quantifies the abduction between particular fingers. A set of 14 sensors 
allows the complexity of various finger movement patterns or gestures to be captured with a 
maximum sampling rate of 100 Hz and amplitude resolution of 8 data bits. The gloves were linked 
to an in-house-built EVSENG system (J. Wackermann, T. Sieger) for synchronization with the 
MRI scanner and on-line recording of the information from the glove. EVSENG was written to 
communicate with the glove on the low-level (i.e. reading data directly from port), but a high-
level interface is also possible via libraries and routines supported by the producer. 
2.2.4. EXPERIMENTAL PARADIGM 
 A block-based motor paradigm was conceived to investigate the brain activity associated 
with the motor performance. Consecutive movement and rest epochs, each lasting 10 s, recurred 
25 times, resulting in 50 blocks with a total session length of 500 s. During rest epochs, a visual 
‘rest signal’ (centered static red fixation cross on a black background) was presented on a 
projection screen, whereas during movement epochs, 10 pacing ‘movement cues’ (yellow square 
behind the fixation cross displayed for 100 ms) were presented with a frequency of 1 Hz. While 
viewing the ‘rest signal’, patients were instructed to retain motionless with their arms in a resting 
position. During movement epochs, patients had to perform a unilateral index finger-thumb 
opposition whenever the ‘movement signal’ appeared. For ideal performance, a session would 
consist of a total of 250 distinct unilateral movements. The first measurement session started with 
right-hand movements and was subsequently repeated for the contralateral hand in the particular 





(fully clenched fist followed by one index finger-thumb opposition) to allow the flexor sensors to 
reach their peak values and accommodate the amplitude dynamic range. 
 A two-by-two factorial design with within-subject factors ‘Hand’ (RIGHT/LEFT) and 
‘Levodopa medication’ (OFF/ON) resulted in four scanning sessions for each patient. 
2.2.5. GLOVE RECORDING PROCESSING 
 For each session, a 14-dimensional kinematic signal was recorded with the glove with a 
sampling rate of 64 Hz. Processing was performed using Matlab® (R2010b, The MathWorks Inc., 
Natick, MA, USA) and subroutines of the SPM8 package (Wellcome Trust Centre for 
Neuroimaging, UCL, London, UK). 
 To consider potential inter/intra-individual differences in the dynamic range of the finger 
movements, a normalization procedure was conducted to obtain consistent scaling of the signal 
amplitude. The calibration sequence was used to detect peak and baseline of the movement, and 
the signal was then normalized accordingly by adjusting the peak amplitude to one. Removal of 
low frequency fluctuations and drifts was achieved by subtracting the output of a fast one-
dimensional median filter (Little and Jones, 2010) with a 20-s window from the original signal. 
Substantial amount of high frequency quantization noise was primarily present in signals 
recorded from less active sensors with the restrained dynamic range. Wavelet-based de-noising 
(Donoho, 1995) was applied in order to remove the noise using the global thresholding and a ‘db3’ 
wavelet filter family. 
 Glove waveforms were first analyzed independently on a behavioral level. Data-driven 
filtering using principal component analysis (PCA) (Roweis and Ghahramani, 1999) was 
performed to tease apart the global/deterministic and residual/stochastic features of movement. 
For a comprehensive description of data-driven filtering using PCA, see Daffertshofer et al. 
(Daffertshofer et al., 2004). The global pattern represented a coherent, dominant pattern (the 
finger tapping movement itself) and was calculated for each session by reconstructing the 14-
dimensional dataset with principal components explaining more than 90% of the data. Remaining 





reflected movement deviations in participants’ performance. Variance of each filtered waveform 
was calculated and averaged across sensors to obtain the average variance of a session for both the 
global and residual movement pattern. The variances of a session were separated and averaged 
across particular levels of experimental factors (RIGHT, LEFT, OFF, ON) and statistically analyzed 
inter-individually using analysis of variance with repeated measures (rmANOVA) with IBM SPSS 
Statistics 19. 
 Pre-processed glove recordings were first synchronized with the timing of MR images 
acquisition. To build a personalized regressor as input to the individual-level fMRI design matrix, 
time-courses from 14 glove sensors in a session were merged using two distinct approaches based 
on linear Gaussian models. (i) The ‘mean approach’ resulted in a waveform computed from the 
average of all 14 session-specific waveforms. (ii) The ‘eigenvariate approach’ reflected the session-
specific movement recordings in terms of the projection of glove data on the first principal 
component, which explained the highest proportion of variance of the input observations. This 
calculation was based on PCA. Both mean and eigenvariate versions of waveforms were corrected 
for outliers by replacing them with maximal/minimal values in the non-outliers range. Outliers 
were defined as data points, which were more than 1.5 times the interquartile range above the 
third or below the first quartile. Frequency spectra of all waveforms were observed, to verify the 
absence of any restlessness and rhythmic motions in frequency band of 4-7 Hz (i.e. resting 
tremor/dyskinesias) during resting phase of the task. Furthermore, when no significant peaks of 
movement performance were detected within data values of resting periods, they were adjusted to 
zero. Besides spectral analysis of the resting periods we also focused on motor periods of the task. 
No peaks suggesting presence of low (4-6 Hz), intermediate (6-8 Hz) or higher (8-20 Hz) 
frequency of tremor in any patient were observed. Finally, for both approaches the envelope curve 
of the resulting waveform was calculated. To investigate the effect of movement amplitude on the 
brain response, amplitude-invariant versions of the mean and eigenvariate predictors were 
additionally formed by adjusting amplitudes of the waveforms in movement periods to unity. This 
adjustment provided time series sensitive to the timing of the movement execution, but invariant 
in terms of the amplitude of movement performance. Finally, signals were resampled to match 
the number of acquired fMRI time points. Four distinct waveforms – mean; mean amplitude-
invariant (AI); eigenvariate; eigenvariate AI – were constructed for each participant this way and 





2.2.6. FMRI TIME SERIES ANALYSES 
 Data pre-processing and analysis was performed using SPM8 in Matlab® for every session 
separately. To correct for head movement artifacts, fMRI data were spatially realigned to the first 
image. The individual T1-weighted MP-RAGE dataset was co-registered with the functional 
images, segmented with the unified segmentation approach (UnSA) (Ashburner and Friston, 
2005) and normalized to the Montreal Neurological Institute (MNI) (Evans et al., 1993) T1 
template. Normalization parameters from UnSA were then used to normalize all remaining 
images. In the final stage of pre-processing, the functional volumes were smoothed using an 
isotropic Gaussian kernel of 8-mm full width at half maximum (Worsley and Friston, 1995). 
 Fixed-effects, first-level statistics were performed using a general linear model (GLM). Two 
separate types of models were used: (i) a standard model incorporating a constant baseline term 
and a predictor containing a condition-specific, constant-amplitude boxcar function 
characterized by onsets and durations of task-related epochs. This generic model was generated 
by a conventional procedure standard to SPM that assumed movements coinciding precisely with 
cues presented on-screen. (ii) a kinematic model including the constant term and a custom-made 
predictor – one possible alternative to mean, eigenvariate or their amplitude-invariant/amplitude-
sensitive approaches, calculated from kinematic recordings as described in Section 2.2.5. 
 Further processing was conventional and common to both the standard and kinematic 
approaches. It involved high-pass filtering of a 32-s cutoff for removing the most possible amount 
of low-frequency fluctuations while sustaining no loss of experimental power, first-order 
autoregressive AR(1) model (Bullmore et al., 1996; Penny et al., 2003) for estimating the intrinsic 
correlations between residual errors, and a linear time-invariant (LTI) convolution model 
(Boynton et al., 1996) based on a linear approximation of the BOLD response. The session-specific 
predictor of each modeling approach was convolved with a canonical hemodynamic response 
function (HRF) modeled as the first-order Volterra kernel (Friston et al., 1998b; Josephs and 
Henson, 1999). Parameters of Gaussians modeling were determined by timing characteristics of 
the experiment. Since amplitude-sensitive varieties of kinematic predictors had no baseline-to-
peak unique range, they were additionally standardized by scaling the values (5th to 95th 
percentile) range of each to unity to consequently ensure valid comparisons of ß-estimates 





univariate GLM to calculate parameter estimates and residual errors. The standard model and 
four distinct kinematic models were estimated for each patient and session. Figure 3 illustrates 
standard and one of the kinematic predictors for a particular patient’s session. Contrasting the 
effect of interest (non-constant session-specific regressor of the design matrix) resulted in 
contrast images which were used as input for random-effects group analyses. 
 
Figure 3. Comparison of session-specific predictors of standard and kinematic approaches in individual-level modeling. (left, blue: 
standard approach, generated using experimental timing information and no movement assumptions; right, orange: kinematic, mean 
amplitude-sensitive approach, constructed using average of recorded kinematics from all sensors). Dashed lines indicate the most pronounced 
movement deviations in a measurement session of a particular patient. Standard modeling is not able to capture this variability and reflects it 
in the error term in GLM, likely resulting in biased statistics. 
 To evaluate the effect of dopaminergic medication on brain correlates of finger motion in 
the group of PD patients investigated, both medication conditions were studied separately for 
each hand by estimating one-sample t-test random-effects models. Four models for each level of 
experimental factor were estimated for each (standard, kinematic) modeling approach. The group 





voxels to preserve only clusters corrected for multiple comparisons using the family-wise error 
(FWE) (Friston et al., 1996) rate of p<0.05 at the peak level. The amplitude of activity was 
inspected in regions of interest (ROI) in the left and right precentral gyrus. The ROIs were 
generated using automated anatomical labeling (AAL) atlas (Tzourio-Mazoyer et al., 2002) with 
Marsbar SPM toolbox (Brett et al., 2002). Proper scaling of predictors (unit values) and setting 
contrast levels (absolute sum of unity) in individual-level models ensured their maximal 
interpretability and comparability; the contrast images calculated approximated the percent 
signal change (PSC) directly (Luo and Nichols, 2003). We formed the ‘group-level mean’ and 
‘group-level standard error’ PSC image for each levodopa medication condition and extracted the 
values from ROI and displayed their average for every modeling approach, for every level of 
experimental factors separately. In order to take inter-individual differences into account, PSC 
values were extracted and averaged from the ROI inter-individually. IBM SPSS Statistics was then 
used to calculate rmANOVA with factors ‘Hand’ and ‘Modeling approach’ for both levodopa ON 
and levodopa OFF medication conditions. Hence, the standard approach was compared to each 
particular kinematic approach in a pairwise fashion. Using the same technique, differences 
between particular (mean, eigenvariate) amplitude-invariant and amplitude-sensitive kinematic 
approaches were evaluated. 
 The difference between medication conditions was assessed using a flexible-factorial model 
with within-subjects factors ‘Hand’ (RIGHT/LEFT) and ‘Levodopa medication’ (OFF/ON) by 
choosing the difference between the ON and OFF conditions as an effect of interest. The analyses 
were carried out for both standard and kinematic approaches. An uncorrected threshold of 
p<0.001 with 30 voxels extent was adopted. On the cluster level, an FWE rate of p<0.05 was used 
to control for false positive activations. To assess the amplitude of activity, ROIs in the left and 
right pallidum were defined a priori using the AAL atlas based on previous work of Kraft et al. 
(Kraft et al., 2009) and Feigin et al. (Feigin et al., 2001) revealing the activity in BG in patients on 
and off medication. Then, PSC was calculated for each level of experimental factors using the 
same procedure as described above. Similarly, pairwise statistical comparisons were evaluated 
between the particular modeling approaches for the levodopa ON condition. Since BG were not 
activated in the levodopa OFF medication condition at all (time courses corresponded to noise), 







 Comparing OFF and ON conditions, the UPDRS-III scores dropped significantly 
[F(1,11)=122.52, p<0.001] from 33.5 (9.0) to 9.6 (4.0) (mean value with standard deviation), 
demonstrating the improvement of patients’ motor symptoms in the ON condition. Analysis of 
lateralized hemibody UPDRS-III scores in the OFF condition showed non-significant left/right 
asymmetry suggesting that patients with main involvement of the right or left hemispheres were 
represented equally in our study.  
 
Figure 4. Variability of movement on behavioral level. Each bar represents average variance of movement performance calculated from a 
collection of measurement sessions separated for each level of experimental factors ‘Hand’ and ‘Levodopa medication’; displayed as mean + 
standard error. A: Average variances of global movement pattern representing the most coherent parts of glove recordings – finger tapping 
itself. Main effect of ‘Levodopa medication’ is significant (p<0.001) and an interaction between ‘Levodopa medication’ and ‘Hand’ is significant 
(p<0.05). B: Average variances of residual movement pattern representing stochastic, variable quantity of participants’ motor behavior. Main 
effect of ‘Levodopa medication’ is significant (p<0.001). a.u. - arbitrary unit. 
 Behavioral analyses of the hand revealed a significant increase in the movement variability 
in the ON condition compared to OFF in both global [F(1,11)=14.83, p<0.001] and residual 
[F(1,11)=33.61, p<0.001] movement patterns (Figure 4). Moreover, a significant interaction between 
RIGHT/LEFT hand tapping and the OFF/ON medication condition was found in the global 





absent in the course of the experiment in all our patients, which was confirmed by analysis of the 
glove motion during resting periods of the task. 
 
Figure 5. Random-effects parametric maps showing brain correlates of right finger movements with and without dopaminergic 
medication. Maps were obtained by separate analysis (one sample t-test) of both medication-free (OFF) and medication (ON) conditions on 
the group level (top, blue: group maps obtained by standard first-level modeling without further assumptions on motor performance; bottom, 
orange: group maps obtained by mean kinematic modeling technique taking motor performance into account). The brain correlates of left 
finger movements are not shown here, nevertheless resulted in a similar activity pattern as right finger movements, with a cortical cluster 
located in the contralateral hemisphere. Maps were adjusted with a threshold of p<0.001; uncorrected and extended to 150 voxels to show 
only significant clusters (p<0.05; FWE corrected) on the cluster level. FWE - Family Wise Error. kC - number of activated voxels in cortical 
cluster. kS - number of activated voxels in subcortical cluster. 
 FMRI analyses performed for each hand and both medication conditions independently, 
with the purpose of showing neural correlates of finger movements, revealed brain activity in the 
primary motor cortex in the hemisphere contralateral to finger tapping. However, for each hand, 
a decreased extent of activity in the primary motor cortex was observed with levodopa intake 





(BG) after levodopa administration. Comparing OFF and ON separately, a sensitivity increase in 
the extent of activity using kinematic modeling compared to the standard one was found (Figure 
5; see kC, kS). All kinematic approaches showed significantly higher amplitude of activity 
compared to the standard approach, in particular in the precentral gyrus with patients OFF 
(Figure 6A; Table 2) and ON (Figure 6B; Table 2) medication. Also, a significant difference 
between amplitude-sensitive and amplitude-invariant versions of both kinematic approaches was 
observed for both conditions with an exception of the eigenvariate kinematic approach in OFF 
condition (Table 2). 
 
Figure 6. Comparison of modeling approaches as average effect size in anatomical ROI (contralateral precentral gyrus). Each bar 
represents the average value from ROI for the ‘group-level mean’ PSC image, and each error bar the average of the ‘group-level standard error’ 
PSC image. A: Percent signal change for the Levodopa OFF condition and all modeling approaches. B: Percent signal change for the Levodopa 
ON condition and all modeling approaches. AI‡ - amplitude invariant. 
 Investigating the difference between both medication conditions, an increased bilateral 
response to levodopa in the putamen and globus pallidus was revealed. Interestingly, the 
increased BOLD response in the ON condition was present solely within areas of BG and not 
observed in the primary motor cortex. This result was obtained with all modeling methods 
(Figure 7; p<0.001 uncorrected). Strikingly, all variations of kinematic modeling outperformed 
standard modeling and resulted in an extensive sensitivity increase, and provided a larger spatial 





right subcortical cluster obtained with standard modeling did not remain significant after FWE 
multiple test correction. 
 
Modeling approaches compared F-statistic Significance level 
 OFF ON OFF ON 
Standard – Kinematic, mean F(1, 11) = 55.86 F(1, 11) = 108.20 p < 0.001 p < 0.001 
Standard – Kinematic, mean AI‡ F(1, 11) = 59.77 F(1, 11) = 85.43 p < 0.001 p < 0.001 
Standard – Kinematic, eigenvariate F(1, 11) = 63.75 F(1, 11) = 68.21 p < 0.001 p < 0.001 
Standard – Kinematic, eigenvariate AI‡ F(1, 11) = 52.97 F(1, 11) = 77.46 p < 0.001 p < 0.001 
Kinematic, mean  – Kinematic, mean AI‡ F(1, 11) = 23.26 F(1, 11) = 37.86 p = 0.001 p < 0.001 
Kinematic, eigenvariate – Kinematic,  eigenvariate AI‡ F(1, 11) = 3.64 F(1, 11) = 18.15 p = 0.083 p = 0.001 
AI‡ - amplitude invariant. 
Table 2. Main effect of ‘Modeling approach’: percent signal change in anatomical ROI (left, right precentral gyrus) as F-statistics 
obtained by comparing particular modeling approaches in levodopa OFF and levodopa ON conditions. 
 Effect sizes represented as percent signal change in ROIs located in the left and right 
pallidum revealed differences between standard and kinematic modeling approaches even 
without taking inter-individual differences into account (Figure 8B). With regard to inter-
individual variability, rmANOVA showed significance in the main effect of ‘Modeling approach’ 
(p<0.05) with all kinematic approaches. Additionally, a significant difference (p<0.05) between 
amplitude-sensitive and amplitude-invariant versions of both (mean, eigenvariate) kinematic 






Figure 7. Group-level response (ON-OFF) of PD patients to levodopa treatment. Uncorrected threshold of p<0.001 was adopted and maps 
were overlaid on coronal and axial slices (left, blue: group maps obtained by standard first-level modeling without further assumptions on 
motor performance; right, orange: improvement of group-level maps obtained using various kinematic modeling techniques taking 
movement performance into account). AI‡ - amplitude invariant. 
Modeling approach Cluster p-value Number of activated voxels Peak t-value 
 LC RC LC RC LC RC 
Standard 0.021 0.073 64 34 4.27 4.21 
Kinematic, mean 0.017 0.007 68 91 4.37 4.59 
Kinematic, mean AI‡ 0.012 0.025 79 59 4.22 4.28 
Kinematic, eigenvariate 0.010 0.014 80 71 4.20 4.75 
Kinematic, eigenvariate AI‡ 0.029 0.011 80 55 4.21 4.30 
Table 3. List of performance measures revealed by all modeling approaches. LC: left cluster. RC: right cluster. Showed items include p-
values of clusters, numbers of activated voxels and peak t-values. Cluster p-value is FWE (Family Wise Error) corrected for multiple 
comparisons at p<0.05. Number of activated voxels are at the threshold of p<0.001 (uncorrected). AI‡ - amplitude invariant. 
2.4. DISCUSSION 
   
 We investigated the benefit of controlling PD patients’ movement within a finger-tapping 





provide clear evidence of increasing sensitivity in detecting brain activity in PD patients using 
fMRI analyses considering on-line quantification of their motor outcome, compared to generic 
fMRI statistics. 
 
Figure 8. Comparison of modeling approaches as average effect size in anatomical ROI (left and right pallidum). Each bar represents the 
average value from ROI for the ‘group-level mean’ PSC image, and each error bar the average of the ‘group-level standard error’ PSC image. A: 
Percent signal change for the Levodopa OFF condition and all modeling approaches. In contrast to the ON condition, in the OFF condition, the 
basal ganglia were not activated so the data corresponds to noise. B: Percent signal change for the Levodopa ON condition and all modeling 
approaches. AI‡ - amplitude invariant. 
 Solely behavioral analyses revealed substantial differences in motor outcome of PD patients 
between two experimental manipulations requiring repeated sessions, underlining the 
importance of controlling for movement to obtain ‘true’ brain motor responses with fMRI. 
 
Modeling approaches compared F-statistic Significance 
level 
Standard – Kinematic, mean F(1, 11) = 14.83 p = 0.003 
Standard – Kinematic, mean AI‡ F(1, 11) = 13.12 p = 0.003 
Standard – Kinematic, eigenvariate F(1, 11) = 17.29 p = 0.002 
Standard – Kinematic, eigenvariate AI‡ F(1, 11) = 13.28 p = 0.004 
Kinematic, mean  – Kinematic, mean AI‡ F(1, 11) = 5.58 p = 0.038 
Kinematic, eigenvariate – Kinematic,  eigenvariate AI‡ F(1, 11) = 6.24 p = 0.030 
AI‡ - amplitude invariant. 
Table 4. Main effect of ‘Modeling approach’: percent signal change in anatomical ROI (left and right pallidum) as F-statistics obtained by 





 Previous studies investigating levodopa intervention in PD patients with fMRI have 
produced conflicting results (Buhmann et al., 2003; Haslinger et al., 2001; Sabatini et al., 2000). 
Contradictory activity patterns solely in cortical areas such as the supplementary motor area 
(SMA), premotor cortex (PMC) and primary motor cortex (M1) were observed. Surprisingly, no 
activity was detected in subcortical areas such as BG – areas closely associated with PD – possibly 
due to a lack of statistical power with a combination of relatively subtle BOLD responses in those 
areas (Scholz et al., 2000). A more recent study by Ng et al. (Ng et al., 2010) discussing conflicting 
results and interpretations in previous studies concluded that they only investigated the 
amplitude of BOLD response and neglected the spatial pattern of levodopa-induced activity. They 
showed that the main effect of levodopa seems to be a spatial ‘focusing effect’ in both subcortical 
and cortical structures. Work by Kraft et al. (Kraft et al., 2009) exploited a bimanual task to 
increase BOLD responses in BG and showed a bilateral striatal activity in PD patients as a 
response to levodopa treatment. However, only Haslinger et al. (Haslinger et al., 2001) explicitly 
applied the behavioral motor information in fMRI modeling. In our opinion, not taking the 
movement into account in HR modeling may have been a sufficient source of bias in 
interpretations in the aforementioned studies, considering the close relationship between 
patients’ motor performance and dopaminergic medication. Using flexible-factorial random-
effects design, we increased the statistical power by joining data from left and right finger 
movements in one model. We observed a significant increase in the BOLD response in BG as a 
result of levodopa intake in PD patients compared to the medication-free condition, which is in 
agreement with the fMRI results of Kraft et al. (Kraft et al., 2009) and PET results of Feigin et al. 
(Feigin et al., 2001). This supports the idea of a ‘normalizing effect’ of levodopa in putamen in 
cortico-subcortico-cortical circuits of the current pathophysiological model (Alexander et al., 
1986; Rodriguez-Oroz et al., 2009). The response in BG nevertheless appears to a different degree 
of amplitude and extent using either standard or kinematic modeling techniques.  
 In this study, kinematic modeling was performed using the behavioral information 
incorporated in a single regressor, in order to preserve the design efficiency and avoid covariate 
correlation problems because the movement-related regressor is likely to correlate with the 
stimulus-based regressor to a high degree. In the interpretations of fMRI statistical tests, 
correlation is a potential source of ambiguity arising even in the simplest models (Andrade et al., 
1999). Orthogonalizing the regressor in respect to other as a method to tackle correlation 





Duinen et al., 2008; van Rootselaar et al., 2007) is an option; however, it may not solve the 
problem because of decreased sensitivity. The type of modeling framework used in this work is 
especially useful for identifying ‘true’ motor brain responses. Extending the design with another 
stimulus-specific regressor would be particularly interesting for investigating phenomena such as 
neural correlates of motor planning and preparation, sensorimotor integration, or identifying 
motor circuitry responsible for pathological movement. In such cases, the model must 
incorporate experiment information in order to discriminate between actual movement and 
stimuli presentation. 
 We used two types of linear Gaussian models to input glove recordings with hemodynamic 
modeling and compared this approach with generic analysis commonly used in PD motor studies, 
where no quantitative analysis of movement performance is usually reported. In investigating 
motor abnormalities with task-related fMRI, experimental set-up and timing do not provide 
sufficient information for modeling the hemodynamic response adequately, resulting in 
sensitivity decrease. All formerly described kinematic models yielded better fits than the standard 
analysis. We favor the eigenvariate approach as being theoretically more sensitive in reducing the 
dimensionality of high-dimensional data as compared to simple averaging. It preserves the 
dominant task-related movement pattern by assigning higher weights to inputs contributing to it 
while eliminating components likely corresponding to noise. On the other hand, the mean model 
accounts for every single input (sensor) to the same degree, which may result in detecting 
movement deviations specific to the disease, with the penalty of a higher probability for 
introducing noise. In fact, both approaches are often correlated and result in a similar outcome, 
especially if the input data are pre-smoothed (i.e., low-pass filtered). Then the input variables 
have a higher likelihood of co-varying and reflect to similar extents on the first principal 
component, which roughly speaking, is a process of averaging. Both of the approaches presented 
provided a clear increase in sensitivity and we recommend them both for merging multi-
dimensional movement recordings such as those presented here.  
 A clear sensitivity increase was gained by using all variations of kinematic approaches, as 
they accounted for undesired movement variations of participants in hemodynamic modeling. 
This increased the sensitivity in detecting correlations of kinematic models’ predictors with 
measured brain responses and contributed to the reduction of ‘type II’ errors on the individual 





motor outcome significantly, an additive character of the sensitivity increase was also 
demonstrated on the group level by treating both conditions of dopaminergic treatment 
separately and by contrasting their difference. Besides conspicuous and dominant increase of 
sensitivity caused by accurate timing of the HRF, a beneficial effect of considering the amplitude 
of movement using amplitude-sensitive kinematic approaches in forming the HRF is also evident. 
Waldvogel et al. (Waldvogel et al., 1999) stated that an increased neuronal firing rate resulting 
from healthy subjects tapping with a larger amplitude leads to higher synaptic activity, higher 
metabolic demand, and therefore an increased BOLD signal. Their alternative explanation is 
based on the fact that the observed BOLD increase is caused by subjects using additional muscles 
needed to stabilize the hand during large-amplitude movements. However, they did not provide 
an account of the quantitative reciprocal relationship between the two. With one exception 
(eigenvariate kinematic approach, levodopa OFF), we detected significant increases of percent 
signal change using amplitude-sensitive versions compared to amplitude-invariant versions of 
both linear Gaussian kinematic approaches. Considering the conclusions by Waldvogel et al. 
(Waldvogel et al., 1999) and our results, we conclude that there is a mutual relationship between 
an increase in movement amplitude and HR in PD patients, too. In addition to ensuring that 
timing is correct, amplitude of movement in PD fMRI motor experiments must also be controlled. 
2.5. CONCLUSIONS 
 The approach presented here used an fMRI design of alternating movement/rest blocks, but 
might be also suitable for event-related designs. In comparison to block designs, event-related 
designs require more variable tasks in terms of motor performance (to preserve the design 
efficient) and where a precise knowledge of behavioral information such as subjects' motor 
performance is of greater importance according to numerical simulations by MacIntosh et al. 
(MacIntosh et al., 2007). In PD patients, with increasing demands and task difficulty, and with a 
wide spectrum of possible experimental manipulations such as medication, without controlling 
for movement, one can barely detect undesirable movement deviations. Our results demonstrate 





strongly advocate quantitatively controlling for motor performance in order to increase the 












3. MOTOR MATTERS: TACKLING HETEROGENEITY OF PARKINSON’S 
DISEASE IN FMRI STUDIES 
 Previous chapter discussed the decrease of sensitivity, when detecting individual BOLD 
responses in PD participants within fMRI motor experiments in a generic, widely established way 
in imaging community. Proposed method of measuring and quantitatively integrating the actual 
movement performance of PD participants in statistical analyses however dealt mostly with the 
intra-individual deviations, i.e. variations of participants’ motor behavior from an idealized 
experimental paradigm. Inadequate motor abnormalities and the disease features as slowed onset 
and offset of movement; alterations in movement amplitudes, substantially affecting the BOLD 
modeling were taken into account within every session. However, another probable source of bias 
in the modeling of group level activity, the inter-session variability was not accounted for. The 
subject’s motor symptomatic outcome, especially when investigated using an experimental design 
with repeated sessions, changes dramatically. The initial state, the progress of the disease, the 
response to the treatment of the investigated subjects markedly differs among investigated 
patients with PD. A method of utilizing UPDRS-III scores in the modeling of group level activity is 









 Motor symptoms are variably expressed in patients with PD, i.e. patients with identical 
summary motor scale scores may express large heterogeneity in specific motor subscores. In fact, 
various subtypes of the disease have been recognized, such as tremor-predominant PD, akinetic-
rigid type PD and PD dominated by postural instability and gait disorder (PIGD), differing in 
numerous characteristics including the treatment response and rate of progression (Jankovic et 
al., 1990). The clinical heterogeneity may thus reflect a different proportion of involvement in 
relevant brain systems (Albin and Dauer, 2012). Consequently, the results of functional imaging 
studies may be obscured by combinations of various involvement types in the examined PD 
patients' samples.  
 The common practice in fMRI studies analysing intra- and inter-individual variability in PD 
patients is to unify the investigated group by involving subjects with a homogenous, narrow 
distribution of their demographic and clinical characteristics (e.g. age, gender, disease duration, 
disease laterality, clinical scores). In the current fMRI study, we argue that even within a carefully 
selected and seemingly uniform population sample, non-apparent between-subject symptomatic 
variations which require consideration might still be present. We conceived a motor experiment 
with repeated sessions, including pharmacological intervention, which further increased intra- 
and inter-subject variability of the patients' motor behavior. We hypothesized that systematically 
accounting for distinctive symptoms of the disease by utilizing clinical scores in random-effect 
fMRI analyses would have a divergent effect of explaining the variability in the observed data and 
be apparent in the group-model fit. We considered the variability of PD motor symptoms using 
the motor part of the UPDRS (UPDRS-III) from two different perspectives. In the UPDRS-III 'out' 
approach, confounding effects of motor symptoms variability are removed to detect unbiased 
results allowing more straightforward conclusions which are comparable across studies. In the 
UPDRS-III ‘in’ approach, the analysis is aimed on revealing potential linear relationships between 
the particular scores and movement-related brain activity, by detecting the brain regions whose 
activity correlated with the severity of separate motor symptoms, and further illustrating the 










 Twelve male, right-handed patients [mean age 55.9 (SD 6.8) years, range 45-64 years] with 
idiopathic PD [Hoehn-Yahr stage II-III; duration of disease 12.4 (SD 2.1) years, range 9-15 years] 
participated in the study. UK PD Society Brain Bank criteria (Hughes et al., 1992) were used for 
clinical diagnosis. All patients met the criteria for akinetic-rigid type of PD (Schiess et al., 2000). 
The patients underwent the experiment in two treatment conditions, first after an overnight 
withdrawal of dopaminergic medication (OFF condition), and one hour after oral administration 
of 250 mg of levodopa/25 mg carbidopa (ON condition). The motor score of the UPDRS (UPDRS-
III) was assessed by a movement disorders specialist (RJ) in each treatment state, immediately 
preceding the fMRI. 





    UPDRS-III* 
  Total Midline Hemibody Akinesia Rigidity Tremor 
  off on off on off on off on off on off on 
ID Age G DD - - - - L R L R L R L R L R L R L R L R 
1 63 M 15 21 5 4 1 7 7 2 1 4 1 1 0 3 4 1 1 1 2 0 0 
2 53 M 11 45 9 8 2 17 12 2 2 13 8 1 0 3 3 0 1 1 1 1 1 
3 46 M 15 40 13 9 3 11 12 3 4 8 9 3 4 3 3 0 0 0 0 0 0 
4 64 M 14 31 2 4 1 11 13 1 0 9 6 1 0 1 2 0 0 1 5 0 0 
5 58 M 11 26 11 4 3 6 9 2 4 4 4 1 2 2 4 0 1 1 1 1 1 
6 49 M 9 21 9 3 2 10 5 4 2 8 4 4 2 1 1 0 0 1 0 1 0 
7 64 M 14 37 11 5 1 8 17 2 6 6 11 2 5 1 4 0 1 1 2 0 0 
8 53 M 12 37 11 3 2 18 11 4 4 11 7 3 3 3 2 0 0 4 2 1 1 
9 59 M 9 26 6 4 2 12 5 1 0 8 4 0 0 4 1 1 0 0 0 0 0 
10 45 M 14 47 21 9 4 17 13 7 6 10 7 5 3 6 5 1 2 2 1 1 1 
11 64 M 13 31 10 5 3 11 10 3 2 6 3 1 0 3 4 1 1 2 3 1 1 




12.4 33.8 9.8 5.5 2.3 11.6 10.9 2.8 2.9 7.8 6.3 1.9 1.8 2.8 3.2 0.3 0.7 1.3 1.5 0.6 0.5 
(6.8) (2.0) (8.7) (4.5) (2.2) (0.9) (3.8) (3.8) (1.6) (2.0) (2.6) (3.0) (1.4) (1.7) (1.4) (1.3) (0.5) (0.6) (1) (1.4) (0.5) (0.5) 
Table 5. The demographic and clinical characteristics of patients involved in the study. UPDRS-III* - Motor part of Unified Parkinson’s 
Disease Rating Scale. G: gender. DD: duration of the disease (years). OFF: without levodopa medication. ON: with levodopa medication. L: left 
hemibody. R: right hemibody. The last row displays the average and standard deviation as: mean (SD). 
 The experiments were performed according to the declaration of Helsinki and all subjects 
provided a written informed consent prior to their participation. The local ethics committee of 
the General University Hospital in Prague, Czech Republic approved the protocol of the study. 
3.2.2. EXPERIMENTAL DESIGN 
 We applied a block-based visuo-motor paradigm of alternating resting and finger-tapping 
epochs, with each block lasting 10 s. The participants were positioned supine and were instructed 
to remain motionless with their arms in a resting position while perceiving a red fixation cross 
and to perform a unilateral single index finger-thumb tap whenever the movement cue (yellow 
square presented for 100 ms alternating with 1-Hz frequency) appeared on the screen. For each 
particular medication condition, the session was conducted first with the right hand and was 





 In summary, a two-by-two factorial design with the factors ‘hand’ (right, left) and 
‘treatment condition’ (off, on) was formed and resulted in four scanning sessions for each 
participant. 
3.2.3. UPDRS AND UPDRS-III DERIVATIVES 
 The UPDRS is widely used for clinical assessment of impairment and disability in patients 
with PD (Fahn et al., 1987). The original scale comprises four distinct parts (Part I: Mentation, 
Behaviour and Mood; Part II: Activities of Daily Living; Part III: Motor examination; Part IV: 
Complications) with added Modified Hoehn and Yahr staging and Schwab England scale 
(Movement Disorder Society Task Force on Rating Scales for Parkinson's, 2003). The assessor 
rates each item of the scale with a score (0-4), which is linked to common clinically accepted 
terms. The sum of the scores indicates the syndrome severity with a higher summary score 
representing more severe involvement. The UPDRS-III used in this study comprises assessment of 
PD motor symptoms which expresses the severity of the overall motor impairment. 
 For each patient in each treatment condition, the total UPDRS-III score and five symptom 
scores were extracted for further utilization in fMRI modeling. The rigidity score (sum of item 22), 
akinesia score (sum of items 19, 23-26, 31), and tremor score (sum of items 20-21) were calculated 
for the right and left side separately, excluding the head and neck-related subitems. The midline 
score was obtained by summing items 18 and 27-30. The hemibody score was derived as a sum of 
all UPDRS-III items specific to either left or right extremities (sum of items 20-26) for each 
hemibody separately. Based on UPDRS III scores, six patients were predominantly affected in 
their left hemibody, five patients had a predominant right hemibody involvement and one patient 
showed symmetrical involvement. It should be noted that in one case, rigidity prevailed on the 
right side despite a higher left hemibody score.  In three patients with clear asymmetry in 
hemibody scores, rigidity was expressed equally on both sides (see MRI acquisition and analyses 
 The MRI data was acquired using a 1.5T Symphony scanner (Siemens, Erlangen, Germany). 
A T2*-weighted gradient echo echo-planar imaging sequence (TR/TE = 1000/54 ms) was used for 
the fMRI. The functional volume consisted of 10 coronal slices, centred around the central sulcus, 





covering the primary sensorimotor cortex and the basal ganglia. For registration purposes, a T1-
weighted MPRAGE gradient echo acquisition (TR/TI/TE/FA = 2140 ms/1100 ms/3.93 ms/15°) was 
also collected. 
 A standard fMRI analysis pipeline using SPM8 (Wellcome Trust Centre for Neuroimaging, 
UCL, London, UK) with Matlab® (R2010b, The MathWorks Inc., Natick, MA, USA) was carried out 
including realignment, normalization of data using the unified segmentation approach 
(Ashburner and Friston, 2005) and spatial and temporal filtering  (Friston et al., 1998a; Josephs 
and Henson, 1999). First-level maps were generated using a standard general linear model fit  
(Friston et al., 1995) of the pre-processed data with a task-specific predictor. The first-level 
predictors used statistics which were personalized for every patient, by taking into account their 
individual movement performance during the task. MR compatible sensory gloves (5th Dimension 
Technologies, Irvine, CA, USA) were employed to measure the patients’ finger movements and 
then the recordings were utilized to construct a tailored predictor which was more sensitive to 
movement deviations and better reflecting movement-related brain activations than conventional 
hemodynamic response function modeling  (Holiga et al., 2012). 
 To evaluate the group effect of the treatment condition we constructed and fitted the 
flexible-factorial model. First-level data from the left and right hand sessions were pooled in the 
model by specifying the ‘hand’ as a factor to increase the statistical power and to profit from the 
availability of scores specific to left and right body parts (Figure 1). Left hemibody scores and 
symptom scores were used to model data from left hand session and vice versa. In models 
assessing the UPDRS-III and midline involvement not specific to body parts, the same score was 
used twice – once for the left and once for the right body part. Two approaches were used to 
utilize the UPDRS-III scores in the model: (i) The UPDRS-III ‘out’ approach used an additional 
factor ‘treatment condition’ and the particular aspect of UPDRS-III scores as a covariate forming 
an explanatory variable (Figure 9a). (ii) The UPDRS-III ‘in’ employed a particular UPDRS-III score 
or symptom score for correlation with the functional brain responses (Figure 9b). Thus, the 
UPDRS-III ‘out’ integrated an experimental factor (2 levels: ON and OFF conditions) in contrast to 
the UPDRS-III ‘in’ approach. Accordingly, the employed contrasts differed between the two 
approaches. While the UPDRS-III ‘out’ used the ON-OFF contrast as the effect of interest 
considering the score as the nuisance vector, the UPDRS-III ‘in’ used the score as the effect of 





outcome of personalizing the group-level model using both approaches was systematically 
observed on the resulting group activity maps, using each particular score separately. To consider 
the possibility of using multiple scores in one model, Pearson correlation coefficient was 
calculated for each set of UPDRS-III and symptom scores. Finally, six UPDRS-III ‘out’ and six 
UPDRS-III ‘in’ models were estimated, employing total UPDRS-III, midline, hemibody, akinesia, 
rigidity and tremor scores. Furthermore, a conventional model excluding any score was evaluated. 
The parametric maps resulting from each analysis were corrected for multiple comparisons using 
the cluster-level family wise error (FWE) correction. Additionally, corrected alpha values (pFWE-
corr), maximum t-statistic (tpeak) and number of activated voxels (kE) were extracted for all 






Figure 9. Design matrix and applied contrasts illustrating the idea behind both approaches. a) UPDRS-III ‘out’: symptom score is utilized as 
a nuisance factor and the effect of interest represents condition on-off difference. b) UPDRS-III ‘in’: symptom score is employed as an effect of 
interest, hence this statistical design reveals correlations between the functional brain responses and the particular motor score (note the 
contrast above the design matrix). Subject: subject factor. Left: left hand movement. Right: right hand movement. Data obtained in right and 
left movement tasks was pooled together in each model. OFF: off levodopa condition. ON: on levodopa condition. Score: the UPDRS-III score 
or symptom score. 
3.3. RESULTS 
 Parametric maps revealed the group responses of PD patients to levodopa treatment in the 
basal ganglia (Figure 1a). More interestingly, enriching the random-effects model with the specific 
aspect of UPDRS-III using the UPDRS-III ‘in’ and UPDRS-III ‘out’ approaches varied the degree of 
activity substantially (Figure 10).  
 The total UPDRS-III score significantly correlated with the functional responses in the basal 





however completely suppressed the activity corresponding to treatment contrast (ON-OFF), 
when used as a nuisance variable (‘out’ approach, no red clusters on Figure 10b). The midline 
score resulted in a similar pattern as the total UPDRS-III score in both approaches (Figure 10c). 
The hemibody score provided no significant correlation (‘in’ approach, no yellow clusters on 
Figure 10d), but equalized hemibody asymmetry of clinical symptoms and revealed a significant 
difference between treatment conditions (ON-OFF) in the left basal ganglia (‘out’ approach, red 
cluster on Figure 10d). The akinesia score did not provide any significant correlation (‘in’ 
approach, no yellow clusters on Figure 10e); however ‘normalized’ the group symptomatically 
eliciting the most sensitive functional response to levodopa in the basal ganglia (‘out’ approach, 
red clusters on Figure 10e). In particular, the model fit adopting akinesia, despite an additional 
column in the design matrix, evidenced a 63% increase in the volume of activated clusters (Figure 
10e; kE), and their significance levels (Figure 10e; pFWE-corr) compared to the conventional analysis 
(Figure 10a) with no covariate. The rigidity score revealed significant activation in the left basal 
ganglia with an overlay in both the UPDRS-III ‘in’ and UPDRS-III ‘out’ approaches (Figure 10f). 
Contrarily, the tremor score did not show any significant results at the given threshold for both 
approaches (Figure 10g). 
 In summary, the UPDRS-III ‘in’ approach uncovered significant correlations of functional 
brain responses in the basal ganglia with the total UPDRS-III score and the midline score (Figure 
10b, c), irrespective to the treatment. The UPDRS-III ‘out’ approach demonstrated that the highest 
amount of unexplained variability were related to akinesia and rigidity, which most appropriately 
equalized the group’s clinical picture, and thus delivered the most sensitive group response to 
levodopa treatment (Figure 10e, f). Moreover, both approaches may lead to positive results even in 
the same regions, as observed with rigidity, representing the only overlap between the UPDRS-III 
‘in’ and UPDRS-III ‘out’ (Figure 10f). 
 Pearson’s correlation coefficients revealed significant correlations between all scores at the 
rate of p<0.01, except the insignificant correlation between midline and tremor. Correlation 






Figure 10. The group response of Parkinson’s disease patients to levodopa, accounting for individual motor aspects of the disease. First 
column (a) shows results obtained by a conventional analysis not comprising the UPDRS-III scores. Remaining columns represent results 
obtained by considering a particular score using UPDRS-III as an explanatory/nuisance variable (UPDRS-III ‘out’, red label) and as the effect of 
interest to correlate it with the brain responses (UPDRS-III ‘in’ , yellow label). The alpha level was set to p<0.001, uncorrected with the cluster 
extension of k≥30 voxels to correct for multiple tests on the cluster level at the rate of pFWE<0.05. The table displays values obtained by 
statistical analyses: pFWE-corr: corrected p-value of cluster. kE: number of activated voxels in cluster. tpeak: peak t-statistic value in cluster. A value 
in the table is assigned to a particular cluster in correspondence with its location in the picture (left/right basal ganglia cluster). Bottom bar-
plot depicts average of UPDRS-III scores and subscores used in the analyses with standard deviations. LH: left hemibody UPDRS-III score. RH: 
right hemibody UPDRS-III score. 
3.4. DISCUSSION 
 In this paper we have introduced the problem of participants’ symptomatic variability in 
between-subject studies of PD. We revealed the responses to dopaminergic treatment in the basal 





(Holiga et al., 2012) and a positron emission tomography study by Feigin et al.  (Feigin et al., 2001). 
Furthermore, we demonstrated the results of two distinct approaches revealing this variability by 
employing the UPDRS-III scores, which significantly influenced the activation patterns. 
 A fair number of functional imaging studies examining motor circuitry of PD (Jech et al., 
2012; Mallol et al., 2007; Prodoehl et al., 2010; Wu et al., 2011; Wu et al., 2010) embodied the 
UPDRS-III in statistical analyses to reveal correlations between the clinical presentation of the 
disease and the blood-oxygen level dependent (BOLD) signal amplitude (Table 6). 
Correspondingly and alarmingly, the UPDRS-III ‘in’ approach presented here identified a strong 
relationship between the total UPDRS-III score, midline subscore and BOLD responses in the 
basal ganglia regardless of the treatment condition. This finding alone should motivate the 
inclusion of the scores in future motor fMRI studies. The majority of previous studies did not 
consider the heterogeneity of PD symptoms in the analyses at all (Table 6) (Buhmann et al., 2003; 
Cerasa et al., 2012; Gonzalez-Garcia et al., 2011; Haslinger et al., 2001; Helmich et al., 2011; Holden 
et al., 2006; Holiga et al., 2012; Kalmar et al., 2011; Kraft et al., 2009; Macri et al., 2006; Martinu et 
al., 2012; Moraschi et al., 2010; Ng et al., 2010; Palmer et al., 2009a; Palmer et al., 2010; Palmer et 
al., 2009b; Pinto et al., 2011; Sabatini et al., 2000; Sen et al., 2010; Spraker et al., 2010; Tessa et al., 
2010; Tessa et al., 2012; Wu and Hallett, 2005, 2008). In addition to examining correlations, we 
also took advantage of the UPDRS-III scores by means of weeding out variability in the measured 
data originating from symptomatic deviations within/between subjects (UPDRS-III ‘out’). This 
way we were able to equalize particular clinical symptoms between the investigated patients 
intra/inter-individually, thus ‘simulated homogeneity’ with respect to a certain symptom. To our 
knowledge, this and our previous fMRI study (Jech et al., 2012) are the only studies which 
considered using UPDRS-III in the analyses to account for the symptomatic variability of PD. 
Here, akinesia and rigidity were demonstrated as primarily responsive to levodopa treatment, as 
documented by the scores (Figure 10, bottom bar-plot). Thus, incorporating them quantitatively 
in statistical prediction of the group response achieved the uppermost sensitive activity pattern 
representing the patients’ response to levodopa. 
 Several interesting findings which weren’t obvious when using the conventional analysis 
emerged when evaluating UPDRS-III models. As we used the hemibody scores and symptom 
scores in all UPDRS-III models except in the laterally unspecific total UPDRS-III and midline 





sample. Note the particular heterogeneity of lateral involvement of PD in our sample (Table 6). 
Looking at the results obtained accounted for the general hemibody score (Figure 10d), where the 
difference between the treatment conditions was discovered in the left basal ganglia, we might 
speculate that some of the symptoms were predominant in the contralateral right side of the body 
and was improved by levodopa when supressing variability by the summary hemibody score. In 
case the statistical power is sufficient, this might eventually suggest splitting the study group 
further according to the lateral dominance of PD symptoms, or explore the results in more detail 
using more specific subscores.  
 In the present patient’s group, equalizing the akinesia for each hemibody revealed laterally 
unspecific and more sensitive levodopa modulation of activity in BG, confirming that our patients 
were mainly affected by akinesia, and had improvement in both body parts when treated with 
levodopa (Figure 10e). When assessing the results of both UPDRS-III approaches accounting for 
rigidity, we observed an overlap between the results of both UPDRS-III ‘out’ and UPDRS-III ’in’ 
approaches in the left basal ganglia (Figure 10f). We may conclude that this area particularly 
reflects rigidity and simultaneously exhibits sensitivity to levodopa treatment. The asymmetry in 
basal ganglia activation observed with the ON-OFF medication contrast when considering the 
hemibody score might be explained by left/right asymmetry in the rigidity score. This is in 
agreement with the previously observed higher synaptic dopamine increase in the more affected 
hemisphere when levodopa was administered (Tedroff et al., 1996). Higher activation in the left 
basal ganglia may then reflect a higher reaction to treatment because of higher expression of 
rigidity on the right side extremities. Indeed, six patients in our study had rigidity expressed 
predominantly on the right hemibody, three patients on the left side and for three patients it was 
manifested symmetrically. All this is particularly interesting, because with a conventional 
approach alone the sensitivity would be considerably lower and the model would never reveal 
relationships between various symptoms, laterality or the effects of treatment. 
 Since PD is considerably heterogeneous, we advocate systematically checking for scores and 
subscores unquestionably related to the investigated sample using both proposed approaches. 
This might reveal activity patterns specific to the individual aspects of the disease and potentially 
lead to unforeseen findings due to increased sensitivity, or suggest further dividing the 
investigated group of patients in subgroups and analysing them separately. In our case, all 





most sensitive group response. Hence, the proper choice of regressors strongly depends on the 
population sample studied. It is beneficial to study the outcome of the clinical measures and its 
variance separately and select the proper UPDRS-III ‘in’ and/or UPDRS ’out’ approach using the 
particular score or subscore accordingly to research question asked. Moreover, statistical 
limitations regarding the proper covariate choice must also be considered with this type of 
analyses. With the exception of one pair, we observed a high degree of correlation between all 
scores. In a potential multi-score design involving several correlated regressors, besides the 
reduced degrees of freedom, this would lead to inefficient parameter estimates with high 
variance, and the incapability to correctly attribute the effect of a particular score to the model fit.  
 This work is aimed at underlining the strong relationship between the BOLD response and 
the clinical severity of the disease, but also the importance of considering the intra/inter-subject 
variability, even in a pre-unified group of PD patients. Because clinical heterogeneity is not clearly 
defined and is still a matter of debate (Foltynie et al., 2002), we advocate using the proposed 
approaches as leverage for prospective studies involving any group of PD participants for 
personalizing the statistical evaluations, tackling the PD heterogeneity and yielding solid, 
potentially concealed results, considering the clinometric symptomatic involvement to describe 
the heterogeneous nature of PD. Depending on the research question asked, suitable aspects of 
UPDRS-III scores can be selected and incorporated in analyses when using UPDRS-III ‘in’ or 
UPDRS-III ‘out’ approaches, to obtain more reliable statistical inferences allowing for unbiased 











Type of use of clinical 
picture 
Sabatini et al. 2000 6 block 
finger tapping/hand 
movements 
no - - 
Haslinger et al. 2001 8 
event-
related 
hand movements no - - 
Buhmann et al. 2003 8 block finger tappping no - 
correlation (with measured 
motor performance) 
Wu et al. 2005 15 block finger tapping no - - 
Macri et al. 2006 8 block finger tapping no - - 
Holden et al. 2006 6 block finger tapping/toe wiggling no - - 
Wu et al. 2008 15 block 
hand movements/finger 
tapping 
no - - 
Mallol et al. 2007 13 block 
finger tapping/hand 
rotations 
yes UPDRS-III correlation 
Palmer et al. 2009 10 block 
hand squeezing/production 
of force 
no - - 
Palmer et al. 2009 10 block 
hand squeezing/production 
of force 
no - - 
Kraft et al. 2009 12 block power grip hand movements no - - 
Prodoehl et al. 2010 20 block pinch grip yes UPDRS-III correlation 
Wu et al. 2010 15 block finger movements yes UPDRS-III correlation 
Moraschi et al. 2010 6 block finger tapping no - - 




correlation (with HY), 
nuisance factor: measured 
motor performance 
Palmer et al. 2010 10 block 
hand squeezing/production 
of force 
no - - 
Sen et al. 2010 5 block finger tapping no - - 
Ng et al. 2010 10 block 
hand squeezing/production 
of force 
no - - 
Spraker et al. 2010 14 block pinch grip no - - 




Kalmar et al. 2011 10 block finger movement no - - 
Pinto et al. 2011 9 block hand movement, speech no - - 






correlation (with EMG 
recordings) 
González-García et al. 2011 17 block finger tapping no - - 
Wu et al. 2011 18 block finger movement yes UPDRS-III correlation 
Martinu et al. 2012 12 block button presses no - - 
Tessa et al. 2012 19 block hand writing 
no (HY 
staging used) 
- correlation (with HY) 
Holiga et al. 2012 12 block finger tapping no - - 
Jech et al. 2012 12 block finger tapping yes UPDRS-III 
Nuisance factor: UPDRS-III 
and oedema; correlation with 
rigidity and midline score 
Table 6. The summary of fMRI studies investigating motor deficits in Parkinson’s disease. Search performed in PubMed using keywords 
“Parkinson’s”, “fMRI”, “motor task”. All studies involving cognitive aspects were excluded. N: Number of studied patients suffering from 











4. GENERAL DISCUSSION 
 The shaking palsy and its features, as described in an essay by James Parkinson two 
centuries ago (Parkinson, 2002), still remain a puzzle. The interaction of the disease process with 
normal ageing, environmental and genetic factors and the effect of various therapies still need to 
be scientifically challenged in order to understand the disease pathophysiology, discover well-
founded biomarkers and provide a definitive protective cure for this neurodegenerative 
movement disorder (Lees et al., 2009). 
4.1. HETEROGENEITY OF PARKINSON’S DISEASE 
 The pathological definition of the disease is widely accepted as the only and certain way 
how to confirm the idiopathic PD pathology (Foltynie et al., 2002). Yet, patients with very variable 
pathological appearance fulfill the pathological definition for idiopathic PD (Foltynie et al., 2002). 
The pattern and extent of Lewy body distribution as the marker for idiopathic PD pathology 
displays shared characteristics across multiple PD-like syndromes, i.e. progressive supranuclear 
palsy, amyotrophic lateral sclerosis, and Alzheimer disease (Foltynie et al., 2002). Considering the 
post-mortem pathology as a 'certain' way to diagnose PD, it is interesting to note, that a 
significant number of cases are never confirmed neuropathologically. The fact, that the generally 
accepted and most accurate tool for PD diagnostics fails repeatedly, evidences the vastly 





approaching the disease heterogeneity also clinically and combine it with the pathological 
outcome. In fact, the clinico-pathological studies have sought to find the ideal combination of 
clinical criteria, by predicting the pathological evidence using various clinometric features 
(Foltynie et al., 2002). The possible approaches to identify the heterogeneity of idiopathic PD has 
been discussed from different perspectives, to allow for potential classifications of PD. 
Heterogeneity based on clinical phenotype including age of onset, motor phenotype, rate of 
progression and the cognitive impairment has been proposed as well as the heterogeneity derived 
from pathology, genetics, aetiology, and last, but not least, brain imaging (Foltynie et al., 2002). 
4.2. IMAGING APPROACHES TO PARKINSON’S DISEASE 
 Imaging has played a major role in PD research in the last two decades, mainly due to 
intense scientific progress in imaging methods suitable for uncovering the abnormal structure 
and function in PD. Early PET studies have been extremely gainful in attributing the anatomical 
and functional dysfunction to underlying bradykinesia, resting tremor and development of 
medication-related dyskinesias and fluctuations (Brooks, 1999), thus uncovering the distinct 
features of the disease; assigning them to specific brain areas and contributing to unwrapping the 
mysterious heterogeneity. The interest of using the PET/SPECT imaging techniques has shifted 
towards the MRI, which can be attributed to objective reasons as higher spatial and temporal 
resolution of the output images, non-invasiveness and affordability (Stoessl et al., 2011). To our 
knowledge, very few studies investigating PD mechanisms using MRI accounted for possible 
heterogeneities, or studied the heterogeneity explicitly (Chapter 2, Chapter 3). More detailed 
comparisons based on clinical phenotype, or other factors as genetics and environmental 
components have not been performed and still remain to be tackled by imaging scientific 





4.2.1. POTENTIAL FLAWS OF FUNCTIONAL NEUROIMAGING 
 The functional imaging contributed significantly to better understanding of the structure 
and function of the motor system, both affected and unaffected by a movement disorder (Rowe 
and Siebner, 2012). Interpretations of functional imaging studies as PET/SPECT or fMRI are rarely 
based on individual-level inference, as the individual, experimentally induced signal changes are 
small. Typically, the mean signal from a pool of different subjects is assessed from the particular 
voxel to gain better statistical power and increase the signal-to-noise ratio, but paying the cost for 
potential loss of sensitivity due to errors in spatial normalization of individual functional images, 
inhomogeneities (i.e. non-normality) in the signal across subjects, and particularly in idiopathic 
PD, as discussed, the broad heterogeneity, thus potentially different pathophysiological processes 
intermingled altogether. The aim is then to account for these inhomogeneities, which can be 
accomplished by considering the intra-subject, and/or inter-subject inhomogeneities in the 
statistical modeling of neural activity (Mumford and Nichols, 2009). Typical examples are 
incorporating the head movement parameters of participant in the individual-level model of 
neural activity, or age, gender, and other confounding effects in the group-level models. 
 Naturally, investigations exploiting repeated sessions suffer from the additional source of 
inter/intra subject inhomogeneities. Multimodal MR imaging exploring different image 
techniques, as interpreting results incorporated from volumetric analysis, mean diffusivity, 
fractional anisotropy and mean iron deposition from PD patients and controls (Peran et al., 2010), 
which could improve the diagnostic accuracy and sensitivity, is an example (Stoessl et al., 2011). 
Also, studies integrating experimental manipulations (e.g. medication, training) in a pre/post 
factorial design fashion, involving current therapies, suffer from the immoderate variability, 
caused by the repeated measurement sessions. 
4.2.2. EFFECT OF LEVODOPA ON MOTOR FUNCTION ASSESSED BY FMRI 
 Interestingly, the previous motor experiments using fMRI studying the effect of levodopa, 
the gold standard in PD management produced no consensus and reported conflicting results 





al., 2012). While earlier studies discovered changes in cortical structures solely (Buhmann et al., 
2003; Haslinger et al., 2001), the latter studies, on the contrary, provided the evidence of 
subcortical striatal BOLD changes in PD patients after levodopa administration (Kraft et al., 2009; 
Schwingenschuh et al., 2012). Ng and colleagues were the only one to report both cortical and 
subcortical differences between treatment states. These findings are no less than confusing. In an 
event-related design, Haslinger et al. (Haslinger et al., 2001) observed the reduction of primary 
motor/lateral premotor hyperactivity and the increase of SMA and pre-SMA movement-related 
activity following the orally administered levodopa. The unexpected hyperactivity was attested to 
the result of reorganization of impaired motor system, with M1 compensating for disabled 
subcortical circuits. The following work of Buhmann and colleagues (Buhmann et al., 2003) 
utilizing the block design revealed an increase of the BOLD response in M1 and SMA contralateral 
to the affected hand after levodopa intake compared to off condition with de-novo 
hemiparkinsonian patients (having relatively intact/yet not reorganized motor system). They 
argued that the result is in agreement with the basal ganglia-thalamocortical circuit model 
(Alexander et al., 1990). In their study, the hypoactivity of patients’ motor cortex was explained by 
the decreased input from the subcortical motor loop, which is reversible and compensated by 
levodopa. Surprisingly, no changes in subcortical changes were reported, nor 
considered/discussed in these studies. Considering that PD is characterized primarily by the 
dopaminergic deficits in projections from SNc to putamen deep in the brain (Chapter 1) and that 
the putamen is principal structure involved in movement control (Postuma and Dagher, 2006), 
the subcortical changes should be regarded and expected as a result of the levodopa intake.  
 Ng and colleagues (Ng et al., 2010) attributed the conflict from the previous studies to their 
focus merely on BOLD amplitude and not the spatial patterns of activity. They found significant 
decrease in amplitude of BOLD in the contralateral SMA and ipsilateral putamen, thalamus, 
cerebellum and M1 after levodopa, however, they also found the altered spatial variance of 
activity, the 'focusing effect’ of levodopa in thalamus, cerebellum, SMA and M1. The latest studies 
(Kraft et al., 2009; Schwingenschuh et al., 2012) nevertheless discovered the altered and increased 
activity exclusively within the striatum as the effect of levodopa medication. Kraft with colleagues 
(Kraft et al., 2009) related the fact of missing findings in striatal structures in aforementioned 
studies to technical difficulties or to experimental paradigm not sensitive to reveal the small 
magnitudes of BOLD responses in the subcortical structures. Therefore they used the bimanual 





Schwingenschuh and colleagues (Schwingenschuh et al., 2012) in contrast to other studies 
employed the lower limb movements to study the effect of levodopa in idiopathic PD patients, 
revealed the subcortical response to levodopa and attributed the conflicting results of previous 
studies to the variability of used paradigms and their complexity. The abnormal activation 
depends on the specific task (Rowe and Siebner, 2012) and the different amount of attention to 
the task, cueing (internal, external, visual, auditory), type of movement and the part of the body 
used (finger movements, clench movements, ankle movements, squeezing, tapping, producing 
force), automaticity of movement and the learning effect and finally also the type of fMRI design 
(block, event related) might contribute to the different results and interpretations substantially. 
4.3. THE CURRENT WORK 
  We partly agree with the reasoning that the inconsistent paradigms used for studying the 
effect of levodopa in PD patients might have been the cause for conflicting results in 
aforementioned studies; notwithstanding we also argue, that the individual nature of underlying 
pathophysiological processes - already discussed heterogeneity of the disease, which results in 
characteristic clinical and motor outcome of the particular patient, must be regarded individually. 
Therefore, we have proposed a novel method to account for the differences originating from 
manifold nature of paradigms and designs; hence the differing behavioral results in the patients 
(Chapter 2). We observed that the intra/inter-individual differences in movement performance 
lead to insensitive and unreliable results, even by using a simple block fMRI design, which major 
advantage is not being prone to sensitivity declines. With measuring and quantitatively 
employing the movement performance of participants we removed the bias caused by erroneous 
relation of modeled and actual hemodynamic response. Specifically, we compared - in 12 akinetic-
rigid PD patients, different first-level approaches to model finger movement-related activity by 
either boxcar function or by actual finger movement as measured with an MRI compatible glove. 
We found the a the novel approach of modeling the patients' movement-related activity (using 
the glove measurements) was correlated with the measured brain responses to a higher degree, as 





the motor deficits in PD patients. We confirmed that not taking the variability of movement and 
its deviations from the idealized paradigms is indeed decreasing the sensitivity of the 
hemodynamic modeling and consequently leading to biased statistical inferences. It is crucial to 
take inter/intra-individual differences in movement execution into account during fMRI analyses 
and the failure to do so may explain the divergent imaging findings in the literature.  
 Moreover, we have introduced another potential perilous factor in the statistical prediction 
of the BOLD response of PD participants. While Chapter 2 of this thesis investigated the effect of 
incorporating the movement performance in the individual-level modeling, Chapter 3 studied the 
effect of incorporating the clinical picture of participants in the group-level prediction of patients' 
fMRI activity, thus accounting for inter/intra-subject variability caused by heterogeneous nature 
of the disease itself and potentially different involvement of pathophysiological features 
characteristic to a particular patient. Also, response of every individual to dopaminergic challenge 
differs substantially, which constitutes a further aspect in the inter/intra-subject variance and 
emphasizes the vast heterogeneity of the clinical picture of PD. We concluded, that it is necessary 
to model this heterogeneity, even though in a simplistic manner, by using the widely accepted 
and up to date the state of the art scale for PD monitoring - the UPDRS scores. Relevantly to the 
motor nature of the experiment, we presented the influence of systematically including the 
particular motor clinical aspect of the disease (UPDRS-III) into statistical modeling as a covariate 
in a motor fMRI experiment to reveal the group response to levodopa medication. Two distinct 
approaches aimed to answer distinct research questions by tackling the disease heterogeneity 
were presented in this work. One approach is using the particular UPDRS-III score as a nuisance 
factor in the model, to reveal the response of participants to levodopa. This approach simulates 
the 'artificial homogeneity' of PD to a certain degree and hence, by a simplification, is able to 
equalize the symptoms between the patients. For instance, the group investigated in this work 
was categorized as akinetic-rigid and that is why using the akinesia/rigidity scores in modeling 
was capable of equalizing the symptomatic picture of the group of patients to the highest degree 
and delivered the most sensitive correspondence of the model and the measured data - the 
'normalized' group response to levodopa. The second approach is using the scores from a different 
perspective; to correlate them with the individual BOLD responses of PD patients. The question 
whether levodopa-induced clinical improvement is also displayed by an increased BOLD response 
in the basal ganglia has been positively answered this way, by using the particular scores as the 





amount of the unexplained variability resulting in differing activity patterns, allowing for the 
explanation that heterogeneous aspects of the disease were still present in the seemingly uniform 
population sample of studied akinetic-rigid patients. Thus, the heterogeneity of the group must 
be also deemed and quantitatively modeled in the predictions of group fMRI activity to allow for 
proper, unbiased results and interpretations. Previously, no proper formal description and 
consideration of the heterogeneity phenomenon in imaging was proposed (Foltynie et al., 2002). 
The current work (Chapter 3) has formally provided a framework to overcome this problem. 
4.3.1. CURRENT WORK IN CONTEXT OF PATHOPHYSIOLOGY OF PARKINSON’S 
DISEASE AND FUNCTIONAL NEUROIMAING 
 Our observations on the effect of levodopa medication on neural circuitry of PD patients 
(Chapter 2, Chapter 3) are in accordance with the latest fMRI (Kraft et al., 2009; Schwingenschuh 
et al., 2012) and PET work (Feigin et al., 2001) and support the finding that levodopa normalizes 
the disease-associated abnormalities in putamen-related dopaminergic pathways. The striatal 
signal changes were surprisingly not recognized nor discussed in the earlier fMRI studies 
(Buhmann et al., 2003; Haslinger et al., 2001). Our results are also in agreement with the results of 
the fMRI study with MPTP-induced hemiparkinsonian syndrome in primates (Chen et al., 1999), 
where the prominent signal changes of the lateral putamen in the rhesus monkeys were identified 
after levodopa infusion. The earlier studies however revealed the cortical (SMA, M1) 
responsiveness to levodopa, even though the findings partly appear as discordant (Buhmann et 
al., 2003; Haslinger et al., 2001). The response of SMA to levodopa is in line with the basal ganglia-
thalamocortical circuit model-generated hypothesis of functional deafferentiation (Alexander et 
al., 1990). Multiple factors may account for the missing cortical activity in our work. The motor 
task in our studies were, in contrast to studies revealing cortical differences, externally paced and 
relatively simple, hence might not have dominantly engaged the SMA, which was shown to be 
primarily involved in control of more complex and internally-cued movements rather than of 
those cued externally in monkeys (Brinkman, 1984). Another factor, which refers to the principal 
message of this work might of course have been, that the results of our study were more sensitive 





bias and likelihood of artifact-induced sensitivity drops (i.e. head movement in the scanner, not 
modeled incidental movements, pathophysiological heterogeneities in studied group of patients). 
 Nevertheless, our results do not fully support the functional deafferentiation hypothesis 
(Alexander et al., 1990), but are in accordance with a number of studies investigating functional 
abnormalities in motor control of PD patients (Chen et al., 1999; Feigin et al., 2001; Kraft et al., 
2009; Schwingenschuh et al., 2012). This suggests that further studies still need to be conducted to 
uncover the neural mechanisms underlying the effect of the most effective treatment strategy in 
PD, levodopa. Consequently, extended models considering and explaining the changes in striatal 
activity after dopamine replacement therapy might emerge for further and deeper understanding 
of the yet not fully known PD pathophysiology. 
4.4. POTENTIAL BENEFIT AND FUTURE OUTLOOK 
 The methodical technique presented in Chapter 2 can be generalized in several ways for 
utilization in different experimental environments. Especially, it might be useful for increasing 
the sensitivity in the event-related designs, where the paradigm is typically more irregular than in 
block designs, and the events approached as brief singular movements, which makes the 
modeling more challenging and more prone to errors. The internally guided movements are of a 
greater interest in PD investigations, as they have been shown to be impaired to a greater extent, 
than externally triggered movements (Georgiou et al., 1994). This method would allow for an 
assumption-free, experimentally unconstrained evaluation of movement-related brain activity. 
The methodical framework can be adapted for variety of other movement arrangements acquired 
by a MR-compatible multiple-sensor apparatus, such as whole hand movement, squeezing, 
producing force, fist movements, ankle movements, or other.  
 The method presented in Chapter 3 might be employed as a formal depiction of a good 
practice how to account for the disease heterogeneity using the UPDRS scores, to consider the 
disease heterogeneity in fMRI studies with PD patients. Doing so might allow for more accurate 





investigating this incurable malady. Both approaches presented in Chapter 2 and Chapter 3 can be 
regarded and serve as a reference fur prospective studies studying PD with fMRI. As subcortical 
changes have been found to be associated with the motor-related response to levodopa in PD 
patients, significant attention must be paid to the sensitivity of the method, since the functional 
brain responses in subcortical structures are lower by a factor of 3 in comparison to the cortical 
structures (Scholz et al., 2000). Both approaches are able to significantly increase the sensitivity of 
detecting the brain activity in PD using fMRI. The benefit of the current work might be also 
obvious, when used to decrease the bias in studying the unknown effect of novel therapies 
requiring repeated sessions, thus experiencing major variability in clinical outcomes, such as DBS, 
where first fMRI results have been reported already (Jech et al., 2001). All patients investigated in 
the reported studies (Chapter 2, Chapter 3) underwent bilateral DBS of the STN and were 
measured using the task-related and the resting-state fMRI. Future aim is to evaluate this 
extremely valuable dataset and show the functional mechanisms behind the beneficial effect of 
DBS on the patients' BOLD activity. 
4.5. CONCLUSION 
 Functional neuroimaging might be a suitable tool to unmask the puzzling pathophysiology 
of PD, to reveal the outcomes of the follow-up measurements to monitor the disease progression 
or to test the impact of novel therapies. The results of the present work emphasize the high 
potential of fMRI to investigate the degenerated motor circuitry in PD. The application of the 
presented approaches resulted in a significant sensitivity increase in detecting brain activity in 
PD, the removal of flaws in the analyses and interpretations and is therefore of major importance 
for further research applications. Moreover, it formally addressed the significance of accounting 
disease heterogeneity in imaging experiments and might serve as guidance for the prospective 
studies to obtain unbiased results and eventually unveil obscured findings. The aspects of this 
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 Parkinson’s disease (PD) is the second most common neurodegenerative disease after 
Alzheimer’s disease, occurring in over 4.1 million individuals in Western Europe and the world’s 
most populous countries in 2005, expected to more than double in 2030 (Dorsey et al., 2007). A 





dopaminergic neurons negatively affects quality of life and daily life activities of patients as well as 
their caregivers. Despite undeniable clinical advances in management of the disease symptoms 
and rigorous research efforts, the definitive pathophysiological mechanisms underlying the 
disease are still unknown. Furthermore, no neuroprotective cure, nor true pathogenesis-targeted 
therapies have been discovered, demonstrating a critical need for validated diagnostic and 
prognostic biomarkers with a high degree of sensitivity and specificity (Shtilbans and Henchcliffe, 
2012). Although PD has been considered a sporadic disorder, a considerable number of clinical, 
genetic, environmental and protective factors have been reported to be linked with PD, 
demonstrating its multifaceted nature with a high number of interacting and overlying features 
involved in the process of selective dopaminergic cell degeneration, interplaying differently in 
different individuals (Olanow and McNaught, 2008). The complex nature of the disease is further 
expressed by a wide and individual spectrum of clinical presentation, progression and differential 
response of the patients to existing therapies, suggesting that the clinical heterogeneity may 
reflect a different proportion of involvement in relevant brain systems (Albin and Dauer, 2012). 
This underlines the necessity of explicitly considering the heterogeneous character of PD in 
clinical, but also research practice and tailoring the therapeutic approaches to the needs of the 
particular patient. 
 Currently, no therapeutic interventions have been found to be disease modifying, however a 
promising portfolio of novel emerging therapies has been under development (Poewe et al., 2012). 
Since introduction of levodopa into clinical practice almost five decades ago, dopamine 
replacement therapies have been the most efficacious and used strategies to control the motor 
symptoms in PD. Levodopa is still the ‘gold standard’ of  symptomatic efficacy, despite motor 
complications associated with its long-term use as dyskinesias or motor fluctuations (Jankovic 
and Poewe, 2012). Notwithstanding, its administration must be also tailored; the start of levodopa 
therapy and the decision whether to treat the patient with levodopa at all should be adapted to 
the patient’s individual needs, age and other characteristics (Fox et al., 2011). 
 Aforementioned need for specific, sensitive and validated biomarkers for PD fueled the 
researchers in various fields and the search of predictive and diagnostic markers is still ongoing. 
Besides fluid-based (blood, cerebro-spinal fluid, saliva) molecular markers as candidates, various 
established imaging techniques have been used for identifying potential structural and functional 





magnetic resonance imaging (MRI) has been one of the most emerging imaging tools due to its 
objective advantages as non-invasiveness, outstanding spatial specificity of resulting images and 
relatively acceptable availability (Stoessl et al., 2011). In recent years, a specific and booming 
application of MRI, the functional MRI (fMRI), has been widely established. FMRI has the ability 
to localize and study temporally specific, functional metabolic activity of the brain related to a 
specific task controlled by the investigator. Several studies have explored the functional 
abnormalities in PD patients compared to healthy participants during the motor tasks with fMRI, 
however the reported abnormal activity differs considerably among those studies (Rowe and 
Siebner, 2012). The effect of levodopa on function of neural circuits in diseased patients has been 
studied considerably using fMRI and motor tasks too, however no clear consensus was reached 
and the studies reported results which are no less than conflicting (Buhmann et al., 2003; 
Haslinger et al., 2001; Kraft et al., 2009; Ng et al., 2010; Schwingenschuh et al., 2012). While 
differential specificity and simplicity of the task, attention to it, type of cueing, automaticity and 
learning of the performed task among studies has been considered as the potential source of the 
results discrepancies (Rowe and Siebner, 2012), in the present work, another potential bias origin 
is revealed and tackled.  
 We partly agree with the reasoning that the inconsistent paradigms used for studying the 
effect of levodopa in PD patients might have been the cause for conflicting results in 
aforementioned studies. However, we also argue that the individual nature of underlying 
pathophysiological processes - already discussed heterogeneity of the disease, which results in 
characteristic clinical and motor outcome of the particular patient, must be regarded individually. 
In this work, we tackled the variable presentation of the disease from two perspectives.  
 First perspective dealt with the movement performance of participants during the motor 
task. PD is predominantly manifested by motor impairment, which may impede the ability to 
accurately perform motor tasks during fMRI. Both temporal and amplitude deviations of 
movement performance from an idealized paradigm designed by the investigator affect the blood 
oxygenation level-dependent (BOLD) response, which is measured during an fMRI experiment. 
Variable nature of the movement within, but also between the measurement sessions was not 
considered at all in previous studies and as showed, it has a significant effect on revealing the 
functional brain responses of PD patients. Therefore, we have proposed a novel method to 





designs; hence the differing behavioral results of patients during the motor task (Chapter 2). We 
observed that the intra/inter-individual differences in movement performance lead to insensitive 
and unreliable results, even by using a simple block fMRI design, which major advantage is not 
being prone to sensitivity declines. With measuring and quantitatively employing the movement 
performance of participants we removed the bias caused by erroneous relation of modeled and 
actual hemodynamic response. Specifically, we compared - in 12 akinetic-rigid PD patients, 
different first-level statistical approaches to model finger movement-related activity by either a 
boxcar function routinely used in fMRI experiments with PD patients, or  we modeled the brain 
responses with help of actual finger movement of participant measured with an MRI compatible 
glove. We found that the novel approach of modeling the patients' movement-related activity 
(using the glove measurements) was correlated with the measured brain responses to a higher 
degree, as compared to the generic, standard model (using the boxcar function) widely used to 
investigate the motor deficits in PD patients. We confirmed that not taking the variability of 
movement and its deviations from the idealized paradigms by means of amplitude and timing of 
movement is indeed decreasing the sensitivity of the hemodynamic modeling and consequently 
leading to biased statistical inferences and wrong conclusions. It is crucial to take inter/intra-
individual differences in movement execution into account during fMRI analyses and the failure 
to do so may explain the divergent imaging findings in the literature.  
 Moreover, we have introduced another potential perilous factor in the statistical prediction 
of the patients’ BOLD responses. While Chapter 2 of this thesis investigated the effect of 
incorporating the movement performance in the individual-level modeling, Chapter 3 studied the 
effect of incorporating the clinometrics of patients in the group-level for prediction of their fMRI 
activity. The method accounted for inter/intra-subject variability caused by heterogeneous nature 
of the disease itself and potentially different involvement of pathophysiological features 
characteristic to a particular patient. Also, response of every individual to dopaminergic challenge 
differs substantially, which constitutes a further aspect in the inter/intra-subject variance and 
emphasizes the vast heterogeneity of the clinical presentation of PD. To tackle the heterogeneity 
of PD symptoms, most functional imaging studies tend to select a uniform group of subjects. We 
hypothesize that more profound considerations are needed to account for intra/inter-subject 
clinical variability and possibly for differing pathophysiological processes. The same data 
measured and presented in Chapter 2 were investigated. To account for disease heterogeneity in 





Rating Scale (UPDRS-III) were utilized in the group-level model using two approaches either as 
the explanatory variable to regress out the confounds, or as the effect of interest to correlate the 
brain responses with the scores. Employment of the UPDRS-III score and symptom scores was 
systematically tested on the resulting group response to the levodopa challenge, which further 
accentuated the diversity of the diseased state of participants. Statistics revealed a bilateral group 
response to levodopa in the basal ganglia. Interestingly, systematic incorporation of individual 
motor aspects of the disease in the modeling amended the resulting activity patterns 
conspicuously, evidencing a manifold amount of explained variability by the particular score. It is 
necessary to model this heterogeneity, even though in a simplified manner, by using the widely 
accepted and up to date the state of the art scale for PD monitoring - the UPDRS scores. The two 
distinct approaches utilizing UPDRS aimed to answer specific research questions. One approach 
is using the particular UPDRS-III score as a nuisance factor in the model, to reveal the response of 
participants to levodopa. This approach simulates the 'artificial homogeneity' of PD to a certain 
degree and hence, is able to equalize the symptoms between the patients. For instance, the group 
investigated in this work was categorized as akinetic-rigid and that is why using the 
akinesia/rigidity scores in modeling was capable of equalizing the symptomatic picture of the 
group of patients to the highest degree and delivered the most sensitive correspondence of the 
model and the measured data - the 'normalized' group response to levodopa. The second 
approach is using the scores from a different perspective; to correlate them with the individual 
BOLD responses of PD patients. The question whether levodopa-induced clinical improvement is 
also displayed by an increased BOLD response in the basal ganglia has been positively answered 
using the correlation approach. Furthermore, with both approaches, characteristic scores 
described varying amount of the unexplained variability resulting in differing activity patterns, 
allowing for the explanation that heterogeneous aspects of the disease were still present in the 
seemingly uniform population sample of studied akinetic-rigid patients. Thus, the heterogeneity 
of the group must be also accounted and quantitatively modeled in the predictions of group fMRI 
activity to allow for proper, unbiased results and interpretations. Previously, no proper formal 
description and consideration of the heterogeneity phenomenon in imaging was proposed 
(Foltynie et al., 2002). The current work (Chapter 3) has formally provided a framework to 
overcome this problem. 
 According to Lewis and Barker (Lewis and Barker, 2009), the disease heterogeneity might 





predominantly through disruptions in basal ganglia circuitry, given the dominant effects of 
dopamine on corticostriatal loops. We revealed the functional response of PD patients to 
dopaminergic challenge in basal ganglia, in agreement with the recent fMRI studies (Kraft et al., 
2009; Schwingenschuh et al., 2012), however in disagreement with the earlier studies (Buhmann et 
al., 2003; Haslinger et al., 2001), which did not demonstrate subcortical changes related to 
levodopa. While the most recent studies specifically designed their experiments to attain a 
satisfactory sensitivity of the method, the earlier did not. In our opinion, this might account for 
the failure to detect subcortical functional changes. The functional brain responses as measured 
by fMRI in subcortical structures are lower by a factor of 3 in comparison to the cortical structures 
(Scholz et al., 2000), hence the statistical sensitivity is of a major importance. The approaches 
presented in the current work formally focused on the statistical sensitivity and the presented 
methods are able to significantly increase the sensitivity of detecting brain activity in PD using 
fMRI. The benefit of the current work might be also obvious, when used to decrease the bias in 
studying the unknown effect of novel therapies requiring repeated sessions, thus experiencing 
major variability in clinical outcomes, such as deep brain stimulation.  
 Both approaches presented in Chapter 2 and Chapter 3 can be regarded and serve as a 
reference fur prospective studies investigating PD with fMRI. Doing so might allow for more 
accurate evaluations and comparisons of the research outcomes across various imaging centers 
investigating this incurable malady, to obtain unbiased results and eventually unveil obscured 
findings. The aspects of this work might hence support the scientific advances, to help to tackle 
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